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ABSTRACT
Small molecule screening is commonly used to discover lead compounds for
drug development, but it can also be a powerful way to identify chemical probes for
studying biological mechanisms. Our lab uses small molecules to study the mechanisms
by which the protozoan parasite Toxoplasma gondii infects and replicates within its hosts.
In this work, we employed a fluorescence-based assay to screen the Medicines for
Malaria Venture (MMV) Open Access Malaria box for compounds that affect T. gondii
growth. The box contains 400 previously identified small-molecule inhibitors of the
related parasite, Plasmodium falciparum. We identified 79 hits, including a 2,4diaminoquinazoline (MMV006169; IC50=1.15µM) that strongly inhibits T. gondii
intracellular replication and invasion with no evidence of toxicity to mammalian cells.
Extensive structure-activity relationship analyses with T. gondii identified a number of
analogs with changed potency and altered effects on replication and invasion. These
structure-activity analyses provided the information necessary to synthesize a bivalent
chemical inducer of dimerization (CID) containing MMV006169 for use in yeast threehybrid experiments. Yeast growth competition assays showed that this CID is capable of
entering the yeast nucleus, as required for yeast three-hybrid screening. Yeast threehybrid was used in a targeted format to test the hypothesis that MMV006169 works by
inhibiting parasite CDC48, an ATPase involved in trafficking and the degradation of
misfolded proteins. Large-scale cDNA library screening by yeast three-hybrid suggests
that the compound may instead be working through inhibition of a host cell target. This
work has provided insight into how MMV006169 affects the parasite’s lytic cycle and
generated a testable hypothesis for the biologically relevant target of the compound.
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CHAPTER 1: LITERATURE REVIEW

1.1

Introduction to Toxoplasma gondii

1.1.1 The phylum Apicomplexa
The phylum Apicomplexa is diverse, containing 6,000 known and likely more than
one million unstudied obligate intracellular protozoans (Adl et al. 2007). These
organisms are so successful that every vertebrate and invertebrate is parasitized by at
least one species belonging to this phylum (Portman and Slapeta 2014). Apicomplexans
are known for their unique invasive stages, which involve an apical complex of secretory
organelles and cytoskeletal elements (Morrison 2009). This complex is used to aid in the
entry of host cells, which is essential for at least one stage of each organism’s life cycle.
The phylum contains a variety of important veterinary pathogens, all of which have
adopted a parasitic life-style. Neospora caninum has a broad host range; however, it
causes significant economical loss in the cattle industry as infection results in
spontaneous abortion of calves. Treatment of neosporosis is limited by the ability to
detect infection in animals (Dubey et al. 2007). Babesia spp. cause babesiosis, which also
affects the cattle industry, but can impact humans and other domestic animals as well.
Recently, efforts to develop treatments for babesiosis have suggested areas for drug
targeting, but no successful treatments have resulted (Mosqueda et al. 2012).
Apicomplexans are also an important medical concern for humans. Arguably, the
most notorious of the Apicomplexan parasites are Plasmodium spp., which cause malaria.
Between 2000 and 2015, the World Health Organization estimates that of the 218 million
1

people infected by Plasmodium spp., 438,000 lives were lost each year (W.H.O. 2015).
This is due to the continual ability of the parasite to develop resistance to anti-malarial
drugs. Cryptosporidium spp. cause the diarrheal disease cryptosporidiosis. Diarrheal
disease is one of the leading causes of death amongst children under the age of 5, killing
800,000 children annually (Bhutta and Black 2013). Despite its clinical importance, the
drugs available for the treatment of cryptosporidiosis are minimal due to wide efficacy
ranges in patients (Manjunatha et al. 2016). As a theme, despite the broad host range and
worldwide prevalence of Apicomplexans, minimal therapeutics are available to treat the
infections they cause.

1.1.2 Toxoplasma gondii and toxoplasmosis in humans
Toxoplasma gondii infects nearly 30% of the United States population, and up to
80% of the population in some parts of the world, causing a condition termed
toxoplasmosis (Dubey 1994, Remington et al. 1995, Pappas et al. 2009). The life cycle of
T. gondii has both sexual and asexual phases and involves three infectious forms of the
organism: sporozoites, tachyzoites, and bradyzoites (Chapter 1 – Figure 1). The sexual
phase takes place in the definitive host, which can be any domestic or wild feline (Tenter
et al. 2000). Oocysts containing sporozoites form within the intestines and are shed in
feline feces. Humans and other intermediate hosts ingest these oocysts, which then
transform into tachyzoites (Speer et al. 1995). Tachyzoites, the fast replicating asexual
form of the parasite, are responsible for the lytic cycle (Chapter 1 – Figure 2). The lytic
cycle begins when a tachyzoite invades a host cell. T. gondii has a broad host-range and
2

is capable of invading any nucleated mammalian cell (Black and Boothroyd 2000). The
parasite replicates via endodyogeny within a newly formed parasitophorous vacuole.
Once the host cell is filled with tachyzoites, the parasites secrete perforin-like protein 1
(TgPLP1), and egress from the host cell (Kafsack et al. 2009). These newly egressed
tachyzoites then disseminate and invade new host cells. It is the repeated cycling of host
cell lysis via invasion, replication, and egress that cause noticeable symptoms in humans.
When the tachyzoite senses stress, such as assault by immune cells or lack of
nutrients, the parasite will undergo a stage conversion to form the bradyzoite. The
bradyzoite is the slow-replicating asexual form of the parasite. During stage conversion,
the parasitophorous vacuole is modified to form a cyst wall and matrix within which the
bradyzoite resides (Weiss and Kim 2000). The resulting tissue cysts are commonly found
in the brain, heart, skeletal muscle, and retina of the host. Within these cysts, the parasite
can lay dormant until the host immune system becomes impaired. At this point the
bradyzoites convert back to tachyzoites and the lytic cycle begins again.
Toxoplasmosis can manifest in a variety of ways depending on the immune state
of the host. The immunocompetent host typically experiences either no symptoms at all,
or mild flu-like symptoms that are self-limiting and resolve within a few weeks. In the
immunocompromised individual, toxoplasmosis typically manifests as toxoplasmic
encephalitis (TE) or ocular toxoplasmosis. Toxoplasmic encephalitis (TE) is commonly
caused by the reactivation of a chronic T. gondii infection that manifests as hemisensory
loss, visual field defects, headache, weakness, disorientation, seizures, coma, and death
(Luft and Remington 1992). TE is of particular importance in AIDS patients as it is often
3

diagnosed before the patient knows of their HIV-status (Porter and Sande 1992). As such,
it is the most common infection of the central nervous system for those not receiving
appropriate anti-retrovirals (Walker and Zunt 2005). Ocular toxoplasmosis results from
the mass infection of the eye tissue and immune cells, resulting in necrosis and retinal
pigment epithelial cells migrating to, entering the eye, and aiding in phagocytosis (Jones
et al. 2006). In the United States, ocular toxoplasmosis is considered the most common
infection of the retina (Jones and Holland 2010). Congenital toxoplasmosis has severe
effects on neonates, including spontaneous abortion, retinochoroiditis, and cerebral
calcifications (Dubey and Jones 2008).
In humans, transmission of infection can take place through carnivorism, a
fecal-oral route, or congenitally. In 1965, it was shown that the consumption of
undercooked meat containing tissue cysts resulted in increased levels of T. gondii
seropositivity in a population of children. The connection between infection and
carnivorism was later confirmed epidemiologically by looking at seropositivity in areas
known for consumption of raw meat. It was shown that 80% of the adult population
tested in Paris was positive for T. gondii specific antibodies (Dubey 2014). The fecal-oral
route of infection occurs when humans ingest T. gondii oocysts from cat feces. This route
has been confirmed through experimentation on mice (Dubey et al. 1997). Congenital
transmission occurs when a pregnant woman becomes infected with T. gondii. During
pregnancy, the parasite can pass the placental barrier and infect the fetus. The first record
of a T. gondii-like infection in humans was reported in 1923 in a child born with
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hydrocephalus (Dubey 2014). The child became blind within three months and died at 11
months.

1.1.3 Current treatments and limitations
Despite its prevalence, there are minimal therapeutics available for use in the
treatment of toxoplasmosis due to specificity of drugs for specific forms and life-cycle
stages of the parasite as well as high levels of relapse and serious side effects that result
in the therapeutics’ discontinuation (Tomavo and Boothroyd 1995). The most common
treatment for infection is a cocktail of pyrimethamine, sulfadiazine, and folinic acid
(Derouin and Santillana-Hayat 2000). Pyrimethamine is an inhibitor of dihydrofolate
reductase. While it demonstrates strong anti-Toxoplasma activity, it is associated with
bone marrow suppression and is potentially teratogenic (van der Ven et al. 1996,
Montoya and Remington 2008). To avoid the issue of bone marrow suppression, small
quantities of folinic acid are added to the cocktail. Folinic acid can be used to generate
purines and pyrimidines when dihydrofolate reductase is inhibited. However, the addition
of folinic acid has only been marginally successful, as many patients still suffer from
marrow suppression (Hakes and Armstrong 1983).
Sulfadiazine works in synergy with pyrimethamine by inhibiting dihydropteroate
synthase in the same pathway, and is also associated with side effects; sixty percent of
HIV-patients develop a rash and fever upon sulfadiazine treatment (Porter and Sande
1992, van der Ven et al. 1996). It should also be noted that some anti-retrovirals, such as
Zidovudine, reverse the effects of both pyrimethamine and sulfadiazine (Israelski et al.
5

1989). For patients who are unable to tolerate sulfa drugs, sulfadiazine can be replaced
with clindamycin or azithromycin (Montoya and Liesenfeld 2004, Andrews et al. 2014).
Women that become infected with T. gondii while pregnant are prescribed a course of
spiramycin, which has been shown to reduce transmission to the fetus by 60% (Montoya
and Remington 2008). If congenital transmission has already occurred, the standard
course of pyrimethamine and sulfadiazine must be administered, as spiramycin cannot
pass the placental barrier (Montoya and Remington 2008). These present therapeutics are
insufficient for control of toxoplasmosis not only based on the detrimental side effects,
but also because they are ineffective against the dormant form of the parasite, the
bradyzoite.

1.1.4 The model Apicomplexan parasite
Like other Apicomplexan parasites, T. gondii is a single-celled pathogen that
requires a host cell for survival. T. gondii is the model organism for its phylum. The
asexual, pathogenic form of the parasite can be easily maintained by continuous culture
through a variety of cell lines, such as human foreskin fibroblasts, hTERT, and HeLa
cells. Parasites can also be preserved indefinitely in liquid nitrogen using DMSO as a
cryoprotectant (Roos et al. 1994). Methods for continuous culture of other
Apicomplexans, such as Cryptosporidium spp. are not available, which in turn limits the
ability to genetically manipulate these organisms. Efficient means of preserving
Cryptosporidium are also lacking, meaning that fresh oocysts must be isolated regularly
from animal feces and then prepared for experimental procedures (Gut and Nelson 1999).
6

Animal models for the study of T. gondii infection are plentiful, relevant, and
used for the study of cerebral, ocular, and congenital toxoplasmosis. The mouse model
alone has been used to study acute infection, toxoplasmic encephalitis, and
retinochoroiditis (Dubey 1997, Dubey et al. 1997, Subauste 2012). Other successfully
utilized animal models include: rat, rabbit, hamster, guinea pig, and primate (Luder et al.
2014). Plasmodium spp. can be studied in mouse and non-human primate models;
however, speculation exists as to how relevant these models are (Langhorne et al. 2011).
For example, in cerebral malaria, it is infected leukocytes that accumulate in the brain of
mice, and not red blood cells as seen in human infection (Carvalho 2010). Additionally,
mechanisms for controlling infection in animal models of malaria do not always translate
to control of human infections (Carvalho 2010).
The genome of T. gondii has been sequenced and is readily accessible
(http://toxodb.org/toxo) along with community annotation, gene expression data, ESTs,
and proteomics data (Gajria et al. 2008). Diverse approaches to genetic manipulation
have been developed in the last decade that aid in understanding the complex life cycle of
T. gondii. The development of Δku80 parasite lines, which prevent non-homologous end
joining, have made the generation of tagged proteins, gene deletions, promoter swapping,
and allelic replacements more straight-forward (Fox et al. 2009, Huynh and Carruthers
2009, Sheiner et al. 2011). The recent use of CRISPR technology for genetic
manipulation of T. gondii has dramatically decreased the time needed to clone complex
parasite lines and has been used genome-wide to define essential vs. nonessential genes
(Shen et al. 2014, Sidik et al. 2014, Sidik et al. 2016). Historically, genes have been
7

considered essential only after efforts toward generating a clean deletion have failed.
Now armed with data from a genome-wide CRISPR screen, researchers can move
directly towards the generation of parasites with inducible down-regulation or deletion of
essential genes (Mital et al. 2005, Andenmatten et al. 2012). Taken together, the ability
to continuously culture and preserve parasites, relevant animal models, and abundant
genetic tools make T. gondii the model Apicomplexan parasite.

1.2 T. gondii drug development
1.2.1 Target- and phenotype-based compound screening
Small molecule screening is commonly used to discover lead compounds for drug
development, but it can also be a powerful way to identify chemical probes for studying
biological mechanisms. A more comprehensive understanding of the mechanisms of
infection utilized by T. gondii will lead to the generation of drugs with minimal off-target
effects. Historically, small-molecule screens have taken either a target- or phenotypebased approach. Target-based approaches involve the identification of molecules that
alter the activity of a specific protein target in vitro. This approach comes with the
advantage of having defined assays for use in screening molecules of interest and for
confirming putative targets. Knowledge of the target of a compound can also guide in the
development of meaningful structure activity relationship analyses and toxicology studies
(Zheng et al. 2013). Disadvantages of this approach involve lack of efficacy of
compounds in vivo. Screening assays are not always biologically relevant as the molecule
of interest may not be able to access the particular protein of interest. This approach is
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also limited by our inability to predict mechanisms of biological compensation. When the
goal is drug development, target-based approaches can be limiting as potential chemical
diversity is lost upfront and the ability to discover new targets along the way is reduced.
Phenotype-based approaches are used to identify molecules that induce a desired
effect (phenotype) on an entire cell or organism (Kotz 2012). Advantages associated with
these approaches include knowing that the molecule can enter the cell of interest, the
screening methodology is biologically relevant, and multiple targets can be modulated at
once to create a synergistic effect resulting in a desired phenotype. As mentioned above,
when drug development is a goal, phenotype-based approaches can be associated with
broad chemical diversity that is not limited to interaction with a specific target. As such,
this allows for the identification of new/multiple targets throughout the process.
However, this means that target deconvolution can be more arduous as multiple genes
must be examined at once. SAR is also more difficult to develop as metabolism and cellpermeability must be constant considerations (Khurana et al. 2015). The differences
between target- and phenotype-based approaches can be likened to reverse and forward
genetics respectively. In a reverse genetics approach the goal is to identify a phenotype
associated with a gene disruption, whereas in forward genetics screens one identifies a
gene responsible for a specific phenotype.
Both target- and phenotype-based screens have been used to study T. gondii. In
2010, it was shown that bumped kinase inhibitors (BKIs) can inhibit TgCDPK1 (Murphy
et al. 2010, Ojo et al. 2010). Using structural and sequence-based analysis of the ATPbinding site of mammalian kinases versus TgCPDK1, it was found that TgCDPK1 has a
9

unique glycine gate-keeper residue in its active site. Three novel BKIs were synthesized
to improve the specificity of compound binding. Two of these BKIs (NA-PP2, and NMPP1) were specific, potent inhibitors of TgCDPK1 as determined by a radiometric
scintillation assay, an ATP consumption assay, and co-crystallization.
In 2011, a Hybrid Structure Based method was used to identify small molecules
capable of disrupting the interaction between Myosin A (TgMyoA) and Myosin Light
Chain-1 (TgMLC1) (Kortagere et al. 2011). The approach involved structural modeling
of the TgMyoA-TgMLC1 interaction, custom design of a pharmacophore that could
disrupt this interaction, computational compound library screening, and identification of
the compounds that best match the designed pharmacophore. The identified compounds
were then screened against T. gondii for defects in invasion, and one compound was
chosen as a potential lead for drug development. At this point, no new drugs have
resulted from either study.
While the aforementioned target-based approaches for isolation of lead compounds
was useful to better aid in the understanding of general parasite biology, the majority of
small-molecule screens against T. gondii are phenotype-based. These small-molecule
screens have been completed using diverse compound libraries containing varied classes
of compounds or targeted libraries containing only specific types of compounds.
Complete compound libraries screened against T. gondii have been examined to identify
inhibitors of invasion. Carey et al. screened 12,160 molecules and identified 24 inhibitors
and 6 enhancers of invasion (Carey et al. 2004). In addition to invasion, these compounds
were found to have varying effects on microneme secretion, conoid extension, and
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motility. One compound from this screen, tachypleginA, was shown to target TgMLC1
by formation of an adduct on C58, which decreases the parasites myosin motor activity
(Heaslip et al. 2010, Leung et al. 2014). This compound, however, does have additional
targets and was shown to have cytotoxic effects after 24 hours. The second study looking
for compounds impacting parasite invasion identified WRR-086 (Hall et al. 2011). WRR086 modifies C127 in the gene encoding DJ-1. This mutation results in the inability of the
parasite to attach to host cells and successfully invade. While both of these screens
helped to better understand parasite invasion and other associated processes, no
successful drugs have been developed as a result of these studies.
Kamau et al. screened a targeted library of 527 kinase inhibitors for an effect on T.
gondii growth (Kamau et al. 2012). Fourteen different compounds were identified as
altering (increasing or decreasing) parasite growth kinetics and having varying effects on
motility and parasite morphology. To date, the targets of these compounds in the parasite
are unknown. Recently, a drug-repurposing screen was performed using the Tocriscreen
Total Library of compounds (1,120), which identified tamoxifen and pimozide as
potential anti-T. gondii drugs (Dittmar et al. 2016). While drug repurposing has the
potential to quickly identify new therapeutics, the authors acknowledge that target
confirmation is necessary, since off-target effects may be playing a role in parasite
inhibition. It should now be apparent that simply identifying a compound of interest is
not enough to lead to the development of a successful drug. The process requires
compound optimization and a straightforward approach to target identification.
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1.2.2 SAR studies
Both target- and phenotype-based approaches to drug development require
extensive compound optimization based on the ligand of choice through a process termed
structure-activity relationship (SAR) analyses. SAR analyses can be used to reveal how
biological processes are related to chemical structures. In one sense, they can be used to
improve small molecules of interest by strategically adding and removing portions of a
compound to increase its affinity for a single protein target. In cell culture, one is
working with a homogenous system of a single cell type where a drug may only bind to
one specific target. Once administered to an intact organism, the potential for secondary
and tertiary targets becomes possible. For example, in T. gondii, Compound 2 is an antiparasitic compound effective against multiple targets, including TgCDPK1, TgPKG, and
TgCK1α (Donald et al. 2006). Recently, it was shown that this compound has a fourth
target; TgBRADIN (Odell et al. 2015). To prevent compound promiscuity, SAR can
identify structural analogs with increased compound specificity. For example, the 5aminopyrazole-4-carboxamide chemical scaffold has been shown to be an effective
inhibitor of TgCDPK1. The C-3 substitution of a 2-cyclopropoxy group on this chemical
scaffold resulted in a compound with increased solubility and potency against TgCDPK1
(0.22 µM to 0.089 µM), and was able to better eliminate T. gondii from the brain, spleen,
and peritoneal fluid (Huang et al. 2015). SAR was also used to determine novel substrates
of uracil phosphoribosyltransferase. The study screened 100 different analogs of uracil
and identified 5 novel substrates with increased affinity for the enzyme (Iltzsch and
Tankersley 1994).
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In addition to identifying and increasing potency for protein-binding partners,
SAR is pivotal in ensuring that small molecules can traverse necessary biological
membranes and as such work the same way in vivo as they do in vitro (Lien 1981). A
common limitation of drug development is getting the intact small molecule of interest
within proximity of its intended target. A potent compound may appear to function
perfectly in vitro, but fail when applied to an in vivo model. This lack of an effect may be
due to the drug being degraded to a non-functional form by the pH or enzymes present in
the gastrointestinal tract (Sousa et al. 2008). In addition to host enzymes that may
degrade the drug to a useless product, a score of enzymes provided by the gut microflora
may contribute to degradation. The microbiota mainly digest drugs via hydrolytic and
reductive reactions that result in non-polar byproducts (Sousa et al. 2008). These
byproducts themselves may be useless or, due to their non-polar nature, associate with
fatty tissue and be sequestered from the bloodstream preventing delivery of the drug to its
site of action (Qureshi 2010). In addition to storage in adipose tissue, degraded drug
products can also be secreted through urine without ever being absorbed (Qureshi 2010).
Altering a compound’s lipophilicity can help to ensure it will reach an environment of
interest. For example, if one wishes to design a drug that can pass biological membranes
and find a receptor, the lipophilicity should be increased (Lien 1981). Conversely, if a
one wishes to prevent a compound from passing the blood-brain barrier, the lipophilicity
should be reduced (Lee 1991).
SAR is also useful in making small molecules of interest more “drug-like”.
Lipinski’s rule of five has been considered the standard when designing a membrane
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permeable, easily absorbed drug. The rules include having a molecular weight less than
500 Daltons, a partition coefficient of less than 5 (see above discussion for optimizing
lipophilicity), fewer than 5 hydrogen bond donors, and fewer than 10 hydrogen bond
acceptors (Leeson 2012). By optimizing these qualities, SAR can make a compound
easier to synthesize and alter its pharmacokinetic properties, such that the compound has
an increased likelihood of working in vivo.

1.2.3 Mechanisms for Target Identification
Once a compound of interest has been selected and optimized, one must next
identify the biologically relevant target(s) of the molecule to truly understand any
phenotypes resulting from compound treatment. A variety of approaches for smallmolecule target identification exist, both direct and indirect, each with its own set of
limitations and advantages. Direct approaches to target identification look specifically
at small molecule-target interactions, while indirect approaches look at protein or gene
expression profiling, morphological changes, and sensitivity of the target to the drug to
determine the target. The most common direct approach to target identification is
through affinity chromatography. This technique involves the compound of interest
being derivatized to a solid matrix. One successful use of this technique involved the
derivatization of an analog of trapoxin, K-trap, to a resin matrix. Mammalian cell
extract was run over the column, followed by washing, and two distinct compound
interacting partners were identified (Taunton et al. 1996). In 1999, epoxomicin was
derivatized to biotin at the amino terminus and incubated with cell lysate. The resulting
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mixture was probed by western blot with streptavidin-horseradish peroxidase, and three
catalytic components of the 20s proteasome were identified (Meng et al. 1999).
A phage display approach to target identification involves the biotinylation of
the compound, its immobilization on a streptavidin coated plate, and screening of phage
libraries. The libraries are panned across the plate and any interacting proteins remain
on the plate after washing. The phage is then eluted, phagemid is isolated, and the gene
encoding the target can be sequenced. This technique was successfully used to show
that UQCRB is the target of terpestacin (Jung et al. 2010). Along similar lines, protein
microarrays can be used to identify compound targets. Tagged versions of the
compound are flowed over protein microarrays, washed to remove non-specific
interactions, and the array imaged to determine where the tagged molecule resides. This
approach was validated by showing direct biotin-streptavidin, anti-digoxigen antibodydigoxigen, and FKBP12-AP1497 binding (MacBeath and Schreiber 2000).
These direct techniques are limited by the inherent nature of the compoundtarget interaction. The interaction needs to be high affinity to survive the vigorous
washing steps involved and/or the target needs to be abundant enough to be visualized
on and isolated from a gel for follow-up identification (Burdine and Kodadek 2004).
These approaches also require extensive SAR analyses to ensure the molecule is linked
to the matrix/affinity-label in a manner that still allows it to interact with its unknown
target.
Drug Affinity Responsive Target Stability (DARTS) is an indirect approach to
target identification that does not rely on derivatization of the small molecule (Lomenick
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et al. 2009, Pai et al. 2015). The technique relies on a small molecule stabilizing or
protecting its target from proteolysis. In the proof of principle experiment, human Jurkat
cells were exposed to didemnin B, a known inhibitor of EF-1α, and thermolysin (Crews
et al. 1994). Samples were run on SDS-PAGE gels, coomassie stained, and a single
enriched band (didemnin B and thermolysin treated) was confirmed to be that of EF-1α
(Lomenick et al. 2009). This approach is useful in that it can be used in any cell or tissue
type, is not enzyme specific, and has a simple readout. However, as with the
aforementioned affinity-based approaches, DARTS is limited by the strength of the small
molecule-target interaction.
Genomics-based approaches to target identification involve screening the
expression level of genes in the presence and absence of a compound. Scherf et al.
analyzed the expression levels of 8,000 genes in untreated human cancer cell lines and
then treated those cancer cell lines with over 1,400 compounds of interest (Scherf et al.
2000). Correlations between compound treatments and changes in gene expression were
then mapped, enabling target identification to be performed. An alternate approach is
whole-genome mutagenesis, where one treats mutagenized cells with a compound of
interest and selects for resistant organisms. This has proven useful in the study of T.
gondii where the n-ethyl-n-nitrosourea (ENU) mutagenized genome of resistant parasites
can then be sequenced and the relevant target confirmed (Pfefferkorn and Pfefferkorn
1979, Gubbels et al. 2008, Coleman and Gubbels 2012, Farrell et al. 2014).
Metabolomics- and proteomics-based approaches are similar in that the data set is
analyzed in the absence and presence of the drug, and changes in metabolite or protein
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expression are noted for further hypothesis-driven work (Watkins et al. 2002, Plavec et
al. 2004). Similar to the DARTS approach discussed above, Thermal Proteome Profiling
(TPP) looks at the ability of a small molecule to stabilize, or prevent the denaturation of,
a protein during heating (Savitski et al. 2014). TPP was validated by using human K562
chronic myeloid leukemia cells heated to different temperatures in the presence and
absence of kinase inhibitors (staurosporine or GSK3182571). The resulting cellular
supernatants are analyzed by SDS-PAGE and mass spectrometry to determine which
proteins demonstrate a thermal shift and as such interact with the small molecule
(Franken et al. 2015).
The

aforementioned

indirect

approaches

to

target

identification

are

advantageous in that they require no additional chemical derivations be performed on the
molecule of interest. However, they are limited by the fact that they rarely identify a
single target; rather they reveal only a focused area of cellular physiology in which the
molecule is involved. This becomes further complicated when a compound is
promiscuous and interacts with multiple targets. In most cases, these indirect approaches
must then be followed by direct hypothesis-driven approaches.

1.3 Yeast three-hybrid
1.3.1

Applications
Genetically modified yeast can be used in an alternate approach to small-molecule

target identification. The system was originally described as yeast two-hybrid, in which
the Saccharomyces cerevisiae GAL4 transcription factor was split into two functional
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domains, the DNA-binding domain (DBD) and activation domain (AD). The Gal4-DBD
is incapable of activating transcription unless physically associated with an activation
domain. The DBD was fused to SNF1, a serine-threonine-specific kinase, while the AD
was fused to SNF4, a protein known to associate with SNF1, and is required for it to
function maximally. The yeast genome was also engineered to encode lacZ under the
control of the GAL1 (galactose inducible) promoter. Using yeast expressing both halves
of the transcription factor, it was shown that when SNF1 and SNF4 associate, the
transcription factor is reconstituted and can thus up-regulate the expression of the lacZ
reporter gene by interacting with the upstream activating sequence (Fields and Song
1989). Based on this proof of principle experiment, it was suggested that any two proteins
(a bait and prey) could be fused to either half of a split transcription factor and be used to
demonstrate direct protein-protein interactions.
The yeast-two hybrid system was modified over time to include components from
additional proteins such as the DBD of the E. coli repressor LexA, the AD from the “acid
blob” protein B42, and the AD of the herpes virus protein VP16 (Triezenberg et al. 1988,
Ruden et al. 1991, Golemis and Brent 1992, Gyuris et al. 1993, Vojtek et al. 1993).
Together, the yeast two-hybrid system has been successful in the identification of direct
protein-protein interactions for proteins as small as 8-10 amino acids and as large at 755
amino acids (Heery et al. 1997, Young 1998). The reporter genes used in yeast twohybrid systems have been broadened beyond the use of lacZ. Common “primary
reporters” include genes required for the synthesis of amino acids. The use of these
synthetic genes makes it easy to measure reporter activation by plating yeast on selective
18

media. The most commonly used reporters include LEU2 and HIS3, which are required
for successful yeast growth on media lacking leucine and histidine respectively (Chien et
al. 1991, Gyuris et al. 1993). Colorimetric reporters, such as lacZ and MEL1 can be used
as “secondary reporters” (Aho et al. 1997). Other variations to the yeast two-hybrid
system include the fusion of entire cDNA libraries to the AD in place of a single protein,
which allows for high-throughput screening for protein interacting partners.
The concept of including a linker molecule in the system led to the development
of the yeast three-hybrid methodology (Chapter 1 – Figure 3). First implemented in 1996,
the yeast three-hybrid was used to detect protein-RNA and protein-small molecule
interactions (Licitra and Liu 1996, SenGupta et al. 1996). The system is fundamentally
the same as the yeast two-hybrid, where the activation of a transcriptional reporter is
dependent upon the functional assembly of a transcription factor. Instead of looking at the
direct interaction of two fusion proteins, the system now depends upon the interaction of
each end of a bivalent molecule with those fusion proteins. This bivalent molecule was
named the chemical inducer of dimerization (CID) since it is necessary to dimerize
proteins. Originally, a dexamethasone-FK506-based CID was used in conjunction with
fusion proteins expressing the rat glucocorticoid receptor fused to the LexA-DBD and
human FKBP12 fused to the B42-AD. Upon interaction of the CID with each fusion
protein, the lacZ gene was activated and was detected using media containing 5-bromo-4chloro-indolyl-β-D-galactopyranoside (Licitra and Liu 1996). The same CID was then
used to determine if yeast three-hybrid could be used to identify receptors for a ligand.
They screened a Jurkat cell cDNA library fused to the B42-AD for targets of FK506 and
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isolated two variants of FKBP12, indicating that the system was capable of identifying
known interacting partners of FK506. Yeast three-hybrid methodology has been used to
identify a variety of compound-protein interactions, but it was not until 2002 that the use
of a GAL4-based system was implemented (Henthorn et al. 2002). Since large number of
GAL4-AD containing cDNA libraries are available, this allows for the screening of small
molecules against a variety of organisms and tissue sources. Odell et al. reported the first
use of the yeast three-hybrid methodology in the study of a pathogen in 2015. A CID was
generated linking Compound 2, an imidazopyridine known to inhibit the T. gondii lytic
cycle, to methotrexate. Using this CID and a T. gondii cDNA library, it was found that
Compound 2 inhibits TgBRADIN (Odell et al. 2015).
An alternate approach to yeast three-hybrid was developed using a SNAP-tag
system (Chidley et al. 2011). The CID is comprised of the small molecule of interest
linked to an O6-benzylguanine (BG) derivative. This BG derivative can covalently bind
to a SNAP-tagged DBD. This generates a stable anchor between the CID and DBD. Upon
association of the target protein with the small molecule, reporter genes are expressed as
previously described. Using this approach, eight different CIDs were generated
containing methotrexate, dasatinib, purvanol b, erlotinib, atorvastatin, sulfasalazine,
furosemide, and indomethacin. These CIDs were screened against different human cDNA
libraries where both known and novel targets were identified. This approach is useful in
that the same CID (BG linked to small molecule) can be coupled to glutathione Stransferase (GST). Affinity chromatography can be performed using glutathione
sepharose beads in the presence and absence of GST-tagged CID exposed to cellular
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lysate. The subsequent interacting/target protein can be eluted and identified by western
blot or mass spectrometry.

1.3.2

CID Development
In order to perform a successful yeast three-hybrid screen, one must first obtain an

optimally constructed CID. A typical CID contains a small molecule of interest, a linker
unit, and a compound with a known binding partner (e.g., dexamethasone) (Chapter 1 Figure 3). In an attempt to make the generation of CIDs more straightforward, systems
were designed to work with commercially available components. The first successful
CID generated from these components contained dexamethasone fused to methotrexate,
which was successful in the dimerization of the glucocorticoid receptor with
dihydrofolate reductase (DHFR) (Lin et al. 2000, Baker et al. 2003). A major
consideration when synthesizing CIDs is how to derivatize each component into one
molecule such that it still retains the ability to bind to its target. For example, one must be
certain that methotrexate is properly attached to a small molecule of interest such that it
can still interact with DHFR. Walton et al. performed extensive SAR studies on
methotrexate and was able to identify a functional position for attachment to other
molecules (Walton et al. 2009). Thorough SAR studies must also be performed to
determine how to attach the small molecule of interest to the other end of the linker.
Another important property of CIDs is the length of the linker unit present
between methotrexate and the small molecule of interest. Initially, it was believed that the
chemical nature and length of CIDs had no impact on the ability to bridge proteins. This
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was based on the use of three CIDs containing chemically distinct linker units of varying
lengths. Each of these CIDs was capable of bridging FK506 with FKBP12 (Spencer et al.
1993). In the context of yeast three-hybrid, the impact of CID structure was first analyzed
in 1997, when four FK1012-based CIDs with linkers of varying length and composition
were compared with regards to reporter activation. It was determined that, while all the
CIDs were functional, dramatic differences in potency exist, suggesting that linker length
and composition is important for optimal transcriptional activation (Amara et al. 1997).
In contrast, a similar study was performed with respect to lacZ transcriptional activation
using four different dexamethasone-methotrexate CIDs. The linkers were all generated
using similar chemistry and were comprised of varying length methylene subunits. While
the shortest linker unit (3 methylene subunits) was incapable of activating transcription,
the authors concluded that there was otherwise no correlation between CID size and
transcriptional activation (Abida et al. 2002). Discrepancies between studies may be due
to differences in affinity between CIDs and target proteins, steric hindrance created by
the proteins, or the distance required between proteins for optimal binding (Tran et al.
2013).
CID development is also rate-limited by the number of synthetic steps necessary
to achieve the desired chemical structure. It was reported that generation of a single CID
containing a standard polyethylene glycol (PEG) linker took 21 synthetic steps, 7 of
which were required only to generate the linker unit (Odell et al. 2015). In an attempt to
streamline CID development, the concept of modular CID synthesis was proposed
(Chapter 1 – Figure 4). This approach involves the coupling of methotrexate to an azide
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and the small molecule of interest to an alkyne. Each of these components could be
coupled to varying lengths of PEG linker and then attached via click chemistry to create a
triazole containing CID (Chapter 1 – Figure 4) (Tran et al. 2013). This new approach has
streamlined CID development, making it easier to develop families of CIDs
simultaneously.

1.3.3

False negatives and positives
Yeast three-hybrid technology is limited by the presence of false negatives and

positives in the system. A false negative is defined as a small molecule-protein
interaction, which cannot be detected by the chosen screening method. These false
negatives can be membrane bound proteins, which are not detectable in standard yeast
three-hybrid experiments that require the target protein to be shuttled into the yeast
nucleus. To avoid this issue, the yeast three-hybrid strategy must be chosen carefully to
ensure that the desired proteome is being probed (Bruckner et al. 2009). Steric hindrance
is a common cause of false negatives. Fusing a cDNA library or hypothesized protein
target to a transcription factor may prevent the protein conformation needed to interact
with the small molecule of interest. Troubleshooting can be done with hypothesized
targets by swapping the half of the transcription factor fused to the bait with that of the
prey or by fusing the transcription factor to the other terminus (e.g., fusing the
transcription factor at the carboxy- instead of amino-terminus). Additionally, expressing
these fusion proteins in yeast may result in changes in or the absence of necessary posttranslational modifications to the target protein that prevent small molecule-protein
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interactions from occurring as they would in the target organism. To avoid this issue, the
transcription factor fusion proteins can be co-expressed in the presence of those enzymes
needed for a given post-translational modification (Osborne et al. 1996). Lastly, an
inherent issue in the reproducibility of library screens leads to a large number of false
negatives. Yeast two-hybrid system experiments performed under identical conditions
have been shown to be only 30% reproducible and identify only 12.5% of known targets
(Ito et al. 2001). This means that a number of true positive interactions are often excluded
based on the inability to repeat a given result.
False positive results are obtained when the activation of reporter genes happens
in the absence of a direct small molecule-target protein interaction. The fact that
transcription factor fusion proteins are being overexpressed in a non-native environment
(e.g., the yeast nucleus) can contribute to this problem. As a result, yeast proteins can
interact with the small molecule and parts of the fusion protein resulting in reporter
activation. Since these proteins are not found in the target organism, they are called false
positives. Lastly, “sticky” or misfolded proteins can result in non-specific interactions
with the bait and prey and result in reporter activation. One way to minimize the presence
of false positives in yeast “n”-hybrid systems is to implement a negative selection step
(Chapter 1 – Figure 5). This selection requires the presence of the URA3 reporter gene
under the control of an inducible promoter matching that of the other reporters used in the
yeast “n”-hybrid screen. An aliquot of pre-transformed yeast (containing bait and prey) is
plated on media containing 5-fluoroorotic acid (5-FOA). 5-FOA converts precursor
molecules in the uracil biosynthetic pathway to a toxic product (5-FUMP). This means
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that anything expressing URA3 in the absence of a functional transcription factor will be
killed. Yeast that survives this selection is pooled and used in conjunction with CID to
perform full-scale library screens (Chidley et al. 2011). While this can significantly
reduce the number of false positive interactions seen, it likely will not eliminate them all.
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Chapter 1 – Figure 1: Life cycle of T. gondii

T. gondii oocysts shed in feline feces (1) are consumed by and encyst in intermediate
hosts (2, 3, 5 and 6). Humans become infected through the consumption of tainted food
or water (7), blood transfusions (8), changing kitty litter (7), or through consumption of
undercooked meat containing tissue cysts (6). Once in the human, the parasite can infect
neonates (9, 11) or become cysts in the brain and skeletal muscle (10). Image courtesy of
the CDC; http://www.cdc.gov/parasites/toxoplasmosis/biology.html.
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Chapter 1 – Figure 2: Lytic cycle of T. gondii

T. gondii tachyzoites form an intimate attachment with a host cell and invade through the
formation of a moving junction. Within a parasitophorous vacuole, parasites replicate via
endodyogeny. Parasites egress from the vacuole through a myosin-driven process
coupled with perforin-like protein secretion.
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Chapter 1 – Figure 3: Schematic of yeast three-hybrid system

Yeast three-hybrid systems rely on the separation of a transcription factor into its DNAbinding (DBD) and activation (AD) domains. These domains are expressed as fusion
proteins to DHFR and a cDNA library protein, respectively. Upon addition of a CID
composed of methotrexate, a linker, and a small molecule of interest (above), the
transcription factor will assemble and activate the expression of reporter genes.
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Chapter 1 – Figure 4: A modular approach to CID Synthesis

Schematic of modular CID synthesis with compound of interest shown in pink,
methotrexate in blue, and components of the linker shown in green. From (Tran et al.
2013). Copyright © 2013, Tran et al; licensee MDPI, Basel, Switzerland. Used under
the terms of the Creative Commons Attribution license 3.0.
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Chapter 1 – Figure 5: 5-FOA-based negative selection strategy

Non-self-activating clones do not activate the expression of URA3 (OMP decarboxylase).
5-FOA is metabolized to 5-FOMP, which is non-toxic, allowing yeast cell survival. Selfactivating clones, which induce the expression of URA3, convert 5-FOA to toxic 5FUMP, resulting in cell death. 5-FOA: 5-fluoroorotic acid; 5-FOMP: 5-fluoroorotidine
monophosphate; 5-FUMP: 5-fluorouridine monophosphate. Adapted with permission
from Macmillan Publishers Ltd: Nature Chemical Biology (Chidley et al. 2011),
copyright © 2011.
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CHAPTER 2: SMALL-MOLECULE SCREEN AND STRUCTURE ACTIVITY
RELATIONSHIPS IDENTIFIES 2,4 DIAMINOQUINAZOLINE AS INHIBITOR
OF T. GONDII AND C. PARVUM

[N.B. Some material from this chapter has been published in the following form:
Bessoff, K., T. Spangenberg, J. E. Foderaro, R. S. Jumani, G. E. Ward and C. D. Huston
(2014). "Identification of Cryptosporidium parvum active chemical series by repurposing
the open access malaria box." Antimicrob Agents Chemother 58(5): 2731-2739]

2.1 Introduction
Toxoplasma gondii, the causative agent of toxoplasmosis, is a highly infectious
protozoan parasite infecting roughly 30% of the United States population and up to 80%
of the population in some parts of the world (Dubey 1994, Remington et al. 1995, Pappas
et al. 2009). T. gondii is a member of the phylum Apicomplexa, which contains many
important human (e.g., Plasmodium and Cryptosporidium spp.) and veterinary (e.g.,
Neospora and Babesia spp.) protozoan pathogens. T. gondii has a multi-stage life cycle
involving sexual reproduction in the definitive feline host, and asexual reproduction in a
number of intermediate hosts. In the human host, an acute infection involves the fast
replicating tachyzoite stage invading, replicating in, and egressing from host cells
resulting in cell lysis. The host immune system controls these acute infections by forcing
the parasite to differentiate into the slow replicating bradyzoite. As a result the infection
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becomes chronic with bradyzoites forming tissue cysts, primarily in the brain, cardiac,
and skeletal muscle.
As with other Apicomplexan parasites, there is a need for additional drugs to
treat toxoplasmosis. Current therapeutics available for the treatment of T. gondii include a
cocktail of pyrimethamine, sulfadiazine, and folinic acid (Derouin and Santillana-Hayat
2000). In some cases sulfadiazine can be replaced with clindamycin or azithromycin
(Montoya and Liesenfeld 2004, Andrews et al. 2014). However, due to the high incidence
of relapse and occurrence of side effects, these treatments often must be discontinued
(Porter and Sande 1992, Tomavo and Boothroyd 1995, van der Ven et al. 1996). To date,
no effective therapeutics are available for the treatment of chronic T. gondii infections. In
order to develop better drugs against T. gondii, a deeper understanding of parasite
biology is necessary.
The Medicines for Malaria Venture (MMV) is a partnership founded to reduce
the global burden of malaria by aiding in the development of affordable anti-malarial
therapeutics. Recently, the MMV presented the Open Access Malaria box, a battery of
200 drug-like and 200 probe-like commercially available small molecule inhibitors.
These inhibitors were selected from >19,000 compounds originally identified as
inhibitors

of

erythrocyte-stage

P.

falciparum

by

the

screening

efforts

of

GlaxoSmithKline, St. Jude Children’s Research Hospital, and Novartis (Gamo et al.
2010, Guiguemde et al. 2010, Meister et al. 2011, Spangenberg et al. 2013). The MMV
Open Access Malaria box has been useful in identifying inhibitors of a variety of
apicomplexans including P. falciparum, Cryptosporidium parvum, T. gondii, and
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Theileria annulata (Spangenberg et al. 2013, Bessoff et al. 2014, Boyom et al. 2014,
Hostettler et al. 2016, Van Voorhis et al. 2016).
In the present study, we screen the MMV Open Access Malaria box to identify
inhibitors of T. gondii growth. We focus on MMV006169, which inhibits the growth of
both T. gondii and C. parvum (Bessoff et al. 2014), and find that it also reduces T. gondii
invasion and replication, but has no effect on motility. Extensive structure activity
relationship (SAR) analyses of MMV006169 against both T. gondii and C. parvum are
reported. Lastly, we use yeast three-hybrid technology to test the hypothesis that
MMV006169 interacts with TgCDC48 (TgCDC48Cy and TgCDC48Ap, respectively),
and find no evidence of a direct interaction with either.

2.2 Materials and Methods
2.2.1 Host cell and parasite culture
Human foreskin fibroblasts (HFFs) (ATCC CRL-1643) were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10 units/mL
penicillin G sodium salt, 10 units/mL streptomycin sulfate, 10 mM HEPES, pH 7.2, and
containing 1% heat-inactivated fetal bovine serum (FBS; 1% DMEM) at 37°C, 5% CO2,
and constant humidity. Cells were split by the addition of trypsin to release host cells
from the surface of tissue culture flasks and resuspended in DMEM supplemented as
above but containing 10% FBS (10%DMEM) as described in (Roos et al. 1994) .
T. gondii 2F1 YFP2 tachyzoites (Gubbels et al. 2003), kindly provided by Dr.
Marc-Jan Gubbels, were serially passaged in confluent monolayers of HFFs.
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2.2.2 YFP-based growth assay
Growth of T. gondii strain 2F1 YFP2 parasites expressing yellow fluorescent
protein (YFP) was monitored as previously described (Gubbels et al. 2003) with a few
modifications. Briefly, parasites and HFFs were cultured in HyClone DMEM/high
modified medium lacking phenol red (Thermo Fisher Scientific), supplemented with 10
units/mL penicillin, 10 units/mL streptomycin sulfate, 10 mM HEPES, pH 7.2, and
containing 1 or 10% v/v fetal bovine serum (FBS). Approximately 5x103 HFFs (in 50 µL
medium containing 10% v/v FBS) were seeded into each well of a Special Optics
black/clear 384-well tissue culture-treated plate (BD Falcon) and grown at 37°C, 5%
CO2, and constant humidity. Upon confluence, culture medium was removed, wells were
washed once with culture medium containing 1% v/v FBS, and then replaced with 30 µL
of the same medium. Parasites were harvested by syringe release, passed through a 3-µm
Nuclepore filter (Whatman, Piscataway, NJ) to eliminate host cell debris, and gently
pelleted (1,100 x g, 4 minutes). The resulting parasite pellets were resuspended in
medium supplemented with 1% v/v FBS, counted, and diluted to 1x105 parasites/mL.
Each well of the assay plate was inoculated with 20 µL (2000) parasites, followed by the
addition of test compounds serially diluted from DMSO stocks in culture medium
supplemented with 1% v/v FBS. Assay plates were in incubated at 37°C in 5% CO2, and
fluorescence was read daily for 8 days from the bottom of the plate with the lid in place
using a Synergy 2 microplate reader (BioTek, Winooski, VT). The program was
optimized to a set sensitivity of 60, with excitation filter of 485/20 and emission filter of
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528/20. Positive controls were included in all assays (typically pyrimethamine). The IC50
of each compound was determined as described previously (Bessoff et al. 2014).

2.2.3 MMV Malaria box screening
The 400 small-molecules included in the MMV box (Spangenberg et al. 2013)
were diluted to 1.67 mM in DMSO and consolidated into two V-bottom polypropylene
384-well plates (Whatman, Piscataway, NJ). Vehicle (DMSO) and positive control
(pyrimethamine) wells were scattered throughout the plate. Prior to each use these plates
were warmed to 37°C and centrifuged to ensure compounds were concentrated at the
bottom of each well. Compounds were transferred to the wells of HFF seeded Special
Optics black/clear 384-well tissue culture-treated plates (BD Falcon) using a 384 solid
pin Multi-Blot replicator tool (V&P Scientific) as previously described (Bessoff et al.
2014). Compounds were screened using the YFP-based growth assay at a final
concentration of 2.3 µM in duplicate. Upon completion of the eight-day assay, each well
was visually screened for evidence of compound cytotoxicity, precipitation, and parasite
plaque formation.

2.2.4 ATPase assay
To assess host cell viability in the presence of compounds of interest we
performed ATPase assays using the CellTiter-Glo Luminescent Cell Viability Assay
according to manufacturer's instructions (Promega, Madison, WI). Briefly, Special Optics
white 384-well tissue culture-treated plates (Corning, Corning, NY) were seeded with
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5x103 HFFs (in 50 µL medium containing 10% v/v FBS) and grown at 37°C, 5% CO2,
and constant humidity. Upon confluence, culture medium was removed and replaced with
30 µL of 1% DMEM. Compounds diluted in DMEM were added to each well to a final
concentration of 10 µM (5 µL). Positive and negative controls (sodium azide 143 mM
final and DMSO) were included in each plate. Plates were incubated at 37°C, 5% CO2,
and constant humidity. After 24 hours, an equal volume of CellTiter-Glo Reagent was
added to each well. Plates were agitated by shaking for 2 minutes, followed by
stabilization of the luminescence accomplished by incubating the plate for 10 minutes at
room temperature. Luminescence was recorded using a Synergy 2 microplate reader
(BioTek, Winooski, VT) and presented as relative luminescence units (RLU).

2.2.5 Replication assay
HFFs were grown to confluence on 12 mm circular coverslips in 12-well plates.
2F1 YFP2 parasites were harvested by syringe release, passed through a 3-µm Nuclepore
filter (Whatman, Piscataway, NJ) to eliminate host cell debris, and gently pelleted (1,100
x g, 4 minutes). 4x105 parasites were added to each coverslip in the presence of each
compound of interest. Coverslips were removed 36 hours post infection and incubated in
fixative solution (1X PBS + 4% v/v paraformaldehyde) for 20 minutes, permeabilized
(1X PBS + 0.25% v/v Triton X-100) for 15 minutes, and blocked for 30 minutes in 1X
PBS + 1% w/v bovine serum albumin. Coverslips were incubated in mouse anti-IMC1
(mAb 45.36, 0.75µg/mL) at a 1:1000 dilution in block solution for 1 hour and then goat
anti-mouse IgG conjugated to Alexa 546 (Invitrogen, 2mg/mL) at a 1:500 dilution for 30
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minutes. Coverslips were then sealed to the surface of glass slides using nail polish. One
hundred fields of each sample were counted blindly at 100X on a Nikon Eclipse TE300
epifluorescence microscope.

2.2.6 Invasion assay
Invasion assays were performed in a manner similar to that previously described
(Carey et al. 2004). Harvested 2F1 YFP2 tachyzoites were counted and 5x105 parasites
were added to confluent HFFs grown on 12 mm circular coverslips in 12-well plates in
the presence of each compound of interest (or DMSO). Plates were left at room
temperature for 15 minutes to allow the parasites to settle and were then shifted to 37°C
for 1 hour. Loosely attached parasites were washed away with 1x PBS and each coverslip
was then prepared for immunofluorescence as described above with the following
modifications. Cells were fixed in 1X PBS + 3.1% v/v paraformaldehyde, 0.06%
glutaraldehyde. Fixed coverslips were stained with mouse anti-SAG1 (DG52) diluted
1:200 for 30 minutes and then goat anti-mouse IgG conjugated to Alexa 546 (Invitrogen,
2 mg/mL) at a 1:500 dilution for 30 minutes. Coverslips were then permeabilized and
stained again with mouse anti-SAG1 (DG52) diluted 1:200 for 30 minutes and then goat
anti-mouse IgG conjugated to Alexa 488 (Invitrogen, 2 mg/mL) at a 1:500 dilution for 30
minutes. All intracellular parasites (green) in 100 fields were counted blindly at 100X on
a Nikon Eclipse TE300 epifluorescence microscope.

2.2.7 Two-Dimensional trail assay
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Trail assays were performed similarly to that described previously (Dobrowolski
and Sibley 1996, Carey et al. 2004). Briefly, wells of a Special Optics black/clear 384well tissue culture-treated plate (BD Falcon) were coated with Cell-Tak per
manufacturer’s instructions (Corning, Corning, NY). NaHCO3 (100 mM, pH 8.0) was
used for adsorption. Wells were washed twice with PBS prior to parasite loading. 2F1
YFP2 parasites were harvested, counted, and diluted (in 10mM Hepes buffered Hank’s
Buffered Saline Solution (HBSS) containing 1% v/v dialyzed FBS) to 1.5x107
parasites/mL. Compounds were diluted in Hepes buffered HBSS. To each well
containing Cell-Tak, 20 µL of parasites was mixed with 30 µL of each compound and
incubated for 15 minutes at room temperature followed by 30 minutes at 37°C. The
contents of each well were aspirated, washed, and replaced with 2.5% paraformaldehyde
for 10 minutes. After fixation, wells were treated with 1x PBS + 0.5% w/v bovine serum
albumin for 15 minutes. Parasites were stained with mouse anti-SAG1 (DG52) diluted
1:500 for 15 minutes and then goat anti-mouse IgG conjugated to Alexa 488 (Invitrogen,
2 mg/mL) at a 1:500 dilution for 15 minutes. A thin layer of overlay (1X PBS containing
75% glycerol and 0.05% NaN3) was used to keep wells from drying out. The number of
trails per field was scored blindly across each well in duplicate.

2.2.8 Construction of pGADCDC48Ap and pGADCDC48Cy
Plasmid construction was performed using restriction enzymes and Phusion high
fidelity polymerase purchased from New England BioLabs (Ipswitch, MA). Primers used
were

synthesized

by

Sigma

Aldrich

(The
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Woodlands,

TX).

To

construct

pGADCDC48Ap, the plasmid pGADT7 (Clontech Laboratories, Mountain View, CA)
was digested with SacI and NdeI. CDC48Ap was amplified from RH ΔhxgprtΔku80
cDNA using primers 1 and 2. Purified digested plasmid and CDC48Ap PCR product
were co-transformed into competent AH109 yeast as previously described (Gietz and
Schiestl 2007). Transformants were plated on yeast drop out plates (SC +Glu –leu) and
incubated at 30°C for 48 hours. The resulting plasmid was screened by restriction digest
and DNA sequencing using primers 3-7 (Chapter 2 – Table 5). pGADCDC48Cy was
cloned as described above using primers 8-13 (Chapter 2 – Table 5).

2.2.9 CID competition assay
CID competition assays begin with yeast co-transformed with a plasmid
encoding E. coli dihydrofolate reductase fused to the Gal4 DNA-binding domain
(pGBKeDHFR, cloned by Anahi Odell, unpublished) and a plasmid encoding the Gal4
activation domain fused to TgCPDK1. A single colony was grown at 30°C overnight in 3
mL of synthetic complete liquid media (SC +Glu –trp –leu). The next morning, 4 mL SC
+Glu –trp –leu was inoculated with 200 µL of the turbid yeast culture and incubated for 4
hours with shaking. Log phase cells (determined by OD600) were diluted to 2x105
cells/mL and 25 µL was used to inoculate each test well in a 96-well plate (BD Falcon)
containing 125 µL SC +Glu –trp –leu –his. CID7 (1.5 µL of 2.5 mM or DMSO) and 3AT (1.5 µL of 50 mM) was added to each well. To half of the experimental samples, 1
µL of 40 mM Mtx-MMV006169 was added. Plates were parafilmed and incubated with
shaking (200 rpm) at 30°C. With the lid in place, the OD600 for each well was recorded
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from the bottom of the plate using a Synergy 2 microplate reader (BioTek, Winooski,
VT). Plates were read daily and the assay was terminated when robust growth was
observed in positive control wells that lack Mtx-MMV006169.

2.2.10 Targeted yeast three-hybrid liquid assay
To perform targeted yeast three-hybrid assays a plasmid containing the
hypothesized compound target (pGADCDC48Ap or pGADCDC48Cy) and a plasmid
encoding E. coli dihydrofolate reductase fused to the Gal4 DNA-binding domain
(pGBKeDHFR) was co-transformed into competent AH109 yeast cells, plated on yeast
drop out plates (SC +Glu –trp –leu) and incubated at 30°C for 48 hours. A single colony
of the resulting transformants was grown overnight in 3 mL of synthetic complete liquid
media (SC +Glu –trp –leu). The next morning, 200 µL of turbid yeast culture was used to
inoculate 4 mL of SC +Glu –trp –leu and incubated for 4 hours. Log phase cells
(determined by OD600) were counted and diluted to 2x105 cells/mL and 25 µL was used
to inoculate each test well in a 96-well plate (BD Falcon) containing 125 µL SC +Glu –
trp –leu –his. CID (1.5 µL of 2.5 mM or DMSO) and 3-AT (1.5 µL of 50 mM) were
added to test wells. As a negative control, 1.5 µL DMSO and 1.5 µL 3-AT were added to
wells containing 150 µL of media alone. Yeast expressing pGBKeDHFR and a plasmid
encoding the Gal4 activation domain fused to TgCPDK1 were used as a positive control
(125 µL media, 1.5 µL 2.5 mM CID7, 1.5 µL 50 mM 3-AT, and 25 µL yeast). Plates were
parafilmed and incubated with shaking (200 rpm) at 30°C. With the lid in place, the
OD600 for each well was recorded from the bottom of the plate using a Synergy 2
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microplate reader (BioTek, Winooski, VT). Plates were read daily and the assay was
terminated when robust growth was observed in positive control wells.

2.3 Results
2.3.1 MMV box screen identifies 79 inhibitors of T. gondii growth
Given that many proteins and biochemical processes are conserved between P.
falciparum and T. gondii, we hypothesized that a high percentage of the molecules
included in the MMV Malaria box as inhibitors of P. falciparum would also function as
T. gondii inhibitors. We screened the MMV Malaria box in duplicate against T. gondii
using a YFP-based growth assay (Gubbels et al. 2003). For simplicity and to aid in the
identification of potent compounds of interest, all 400 compounds in the box were added
to assay plates using a pin transfer device that deposits compound at a final concentration
of 2.3 µM (Bessoff et al. 2014). Upon completion of the 8-day growth assay, monolayers
were visually scored for evidence of compound toxicity, insolubility, and host cell
integrity. Seventy-nine compounds, a 19.8% hit rate, were found to alter T. gondii growth
kinetics at 2.3 µM in both replicates (Chapter 2 – Table 1). By comparing these screen
results with data previously generated against C. parvum (Bessoff et al. 2014) and by
closely examining each chemical scaffold for synthetic accessibility, we were able to
narrow our focus down to 5 compounds of interest: MMV000720, MMV403679,
MMV001246, MMV000642, and MMV006169 (Chapter 2 – Table 2). Each of these
compounds was reordered and screened for an effect on T. gondii growth at 11 different
concentrations to extrapolate IC50 values (Chapter 2 – Table 2).
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From these 5

compounds, we chose MMV006169 as our focus based on potency against T. gondii
(1.15 µM), a similar IC50 against C. parvum (1.50 µM) (Bessoff et al. 2014), ease of
chemical synthesis, and the availability of analogs commercially (Chapter 2 – Figure 1).
MMV006169 showed no evidence of host cell toxicity based on visual examination of
wells during each growth assay (maximum 18 µM) or by ATPase assay (10 µM) (Chapter
2 – Figure 2).

2.3.2 MMV006169 inhibits T. gondii invasion, but not motility
The lytic cycle of T. gondii in human cells is a complex, multi-step process (see
Chapter 1). In order to better understand how MMV006169 inhibits T. gondii growth, we
tested individual steps of this lytic cycle to determine if the compound could inhibit
invasion, replication, and/or motility. Parasite invasion is dependent on its ability to glide
along, attach to, and enter host cells, so in a sense, motility is essential for invasion
(Black and Boothroyd 2000, Carey et al. 2004). We tested the parasite’s ability to invade
host cells using a two-color immunofluorescence invasion assay where the surface
antigen, TgSAG1, of intracellular parasites is stained green, and extracellular parasites
are stained red (Carey et al. 2004). Upon quantification of the number of intracellular
parasites per field we found that MMV006169 did inhibit invasion at 10 µM (green,
p≤0.05), but not the lower concentration tested (5 µM, red) compared to vehicle control
(blue) (Chapter 2 – Figure 3A).
Parasite motility was analyzed by 2D trail assay, which exploits the fact that
Apicomplexans deposit surface antigen “trails” as they glide along a substrate
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(Dobrowolski and Sibley 1996). As with the invasion assay, the surface antigen,
TgSAG1, can be stained on a given substrate and these trails can be quantified. No
significant difference in the mean number of trails per field was seen at 5 (red) or 10 µM
(green) compared to a vehicle control (blue) (Chapter 2 – Figure 3B).

2.3.3 MMV006169 inhibits T. gondii replication
T. gondii replication occurs via a process termed endodyogeny, where two
daughter parasites form within the mother (Sheffield and Melton 1968). The mother’s
inner membrane complex, a series of flattened vesicles underlying the plasma membrane,
serves as the scaffold for new daughters (Hu et al. 2002). During cell division, the
mother’s organelles are partitioned between the newly formed daughters and any
remnants are left in a small residual body (Hu et al. 2002). Replication can be quantified
by recording the number (e.g., 2, 4, 8, and 16 or more) of surface stained parasites present
in individual parasitophorous vacuoles over time. Parasites exposed to MMV006169 (5
µM, red, Chapter 2 – Figure 3C) for 36 hours, show a severe replication defect where
98% of the vacuoles seen contain only two parasites.

2.3.4 Structure activity relationship analyses
In order to better understand how MMV006169 inhibits T. gondii replication
and invasion, we expanded our compound library to include structural analogs containing
a conserved 2,4-diaminoquinazoline scaffold (Chapter 2 – Figure 1C, red). We
hypothesized that structural changes to MMV006169 might differentially affect
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replication and invasion. To test this, we purchased 26 and synthesized 48 analogs
containing the 2,4-diaminoquinazoline scaffold, screened each of them by growth assay,
and calculated associated IC50 values. The majority of screened analogs (n=68) ranged in
potency from 0.26 – 11.54 µM, while 6 analogs were found to have IC50 values outside
the range tested (Chapter 2 – Table 3). These compounds were screened in parallel
against C. parvum for inhibitory effects on growth ((Bessoff et al. 2014) and Rajiv
Jumani, personal communication). To differentiate between effects on invasion and
replication, we chose 11 molecules with different potencies against T. gondii and C.
parvum, as well as analogs with major changes to the chemical backbone (Chapter 2 –
Table 4). None of the analogs chosen have toxic effects against the host cells after 24
hours (Chapter 2 – Figure 4). By changing the chemical structure of these compounds we
are able to determine which parts of the compound are essential for an effect on
replication and/or invasion.
The majority of structural analogs examined inhibit T. gondii replication in a
manner similar to the parent molecule (Chapter 2 – Figure 5). However, treatment with
either C-6 or C-10 resulted in only partial inhibition of replication. Here, we define
partial inhibition of replication as having 40% (or more) of vacuoles containing 4-8
parasites per vacuole, with no vacuoles containing 16 or more parasites. C-11 has only a
minor effect on replication, where fewer vacuoles (19% vs. 56%) containing 16 or more
parasites were seen in comparison with the vehicle control. This analog has three
modifications: a trifluoromethyl group on position 3 of R1, a methoxy group on position 8
of R1, and a methoxy group on position 4 of R3. C-4 contains the same modifications on
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R1 and R3, but still inhibits replication. FT14.025.2, not included in the replication
analyses, contains both the modifications on R1 and R2, and can still inhibit T. gondii
growth (Chapter 2 - Table 3). This suggests that the combination of methoxy groups on
R2 and R3 prevent the small molecule from interacting with its target(s). All other analogs
tested appear to inhibit replication, suggesting that having more than 2 modifications (C6 and C-11) to the structure prevent the analog from properly associating with its
replication associated target(s) and that hindrance of the amine on R3 (C-10) leads to only
partial inhibition (an isopropylamine is sufficient).
To analyze the effects of structural analogs on invasion we chose to use a subset
of 5 analogs that included structural modifications to each of three portions of the
molecule (R1, R2, and R3) and also included representatives of each of the three
replication phenotypes described above: inhibition, partial inhibition, and no effect.
These assays suggest that only single modifications made on R1 and R3 retain the ability
to inhibit invasion (Chapter 2 – Figure 6 and Chapter 2 – Table 4). Specifically, the single
modification of R1 on C-1 with a single trifluoromethyl group on position 3 and the
single modification of R3 on C-7 with a methoxy group on position 2, both result in
inhibition of invasion. More than one modification of R1 results in invasion levels equal
to that of the DMSO control (C-5, C-6). C-11, with modifications to R1, R2, and R3
(discussed above), yield invasion levels equivalent to that of DMSO. C-11 does not
inhibit T. gondii growth at concentrations up to 18 µM, this correlates with the lack of an
effect seen in both invasion and replication assays. Similarly, C-11 does not inhibit C.
parvum growth at concentrations up to 10 µM.
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In our replication assays, we only scored vacuoles containing two or more
parasites (i.e., vacuoles in which at least one round of replication had taken place) and the
data are expressed as the percentage of the total vacuoles containing at least two
parasites. However, we noted that the total number of two-parasite containing vacuoles
was low in all compound-treated samples. This led us to ask if the small number of twoparasite containing vacuoles in these samples was due to inhibition of invasion or the
inability to initiate endodyogeny. To test this, we measured the total number of one- and
two-parasite containing vacuoles 36 hours post-infection using the differential two-color
staining strategy typically used in invasion assays (Carey et al. 2004). We found that for
those analogs that caused the most severe invasion defect in a 60-minute invasion assay
(p≤0.0001, C-1 and C-7, Chapter 2 – Figure 6), the number of two-parasite containing
vacuoles was considerably lower after 36 hours than one-parasite vacuoles (Chapter 2 –
Figure 7). This suggests that while the parasites are able to eventually invade, they are
not successfully initiating endodyogeny.

2.3.5 CDC48 does not interact with Mtx-MMV006169
Structure-based searches aimed toward the identification of the target(s) of
MMV006169 identified the inhibitor N2N4-dibenzylquinazoline-2,4-diamine (DBeQ) as a
previously characterized structural analog of MMV006169 (Bessoff et al. 2014). DBeQ
is a potent, reversible inhibitor of an AAA ATPase (ATPase associated with diverse
cellular activities) known as p97 (or CDC48) that is involved in protein trafficking and
the degradation of misfolded proteins (Chou et al. 2011). Previous work suggested that
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p97 functions in the P. falciparum endoplasmic reticulum-associated degradation
(ERAD) pathway and showed that treatment of parasites with DBeQ inhibits growth
(Harbut et al. 2012). We reordered and tested DBeQ for an effect on T. gondii growth and
found it to inhibit growth with similar potency (1.42 µM) to MMV006169, but having
lost potency against C. parvum (4.73 µM) (Bessoff et al. 2014) (Chapter 2 – Table 3,
OSSL_324373). Interestingly, T. gondii has two isoforms of CDC48 (TgCDC48Cy and
TgCDC48Ap) with three different cellular localizations (TgCDC48Cy to the plasma
membrane and endoplasmic reticulum; TgCDC48Ap to the apicoplast) (Agrawal et al.
2009). While CDC48 proteins are highly conserved, these isoforms are of divergent
phylogenetic evolution. Consistent with vertical evolution, TgCDC48Cy exists in a clade
with homologs found in chromalveolates, while TgCDC48Ap groups with proteins found
in organisms that contain secondary plastids (Agrawal et al. 2009). Based on differences
in cellular localization, the function of these proteins is thought to differ. TgCDC48Cy
has been hypothesized to aid in the trafficking of proteins to the proteasome, and also in
helping to bring proteins into the parasite from the host cell. TgCDC48Ap may play a
role in trafficking nuclear-encoded proteins into the apicoplast (Agrawal et al. 2009).
More studies are needed to confirm these hypotheses. Protein alignments comparing each
T.

gondii

isoform

(TgCDC48Cy:

TGME49_273090

and

TgCDC48Ap:

TgME49_321640) with the P. falciparum ortholog (PlasmoDB: PF3D7_1133400) reveal
76 and 37% identity, respectively. This led us to hypothesize that MMV006169 may be
working through inhibition of TgCDC48Cy and perhaps also TgCDC48Ap.
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To test this hypothesis we utilized a targeted yeast three-hybrid system. The
system allows us to directly test small molecule-protein interactions by expressing bait
and prey proteins fused to each half (DNA-binding domain (DBD) and activation domain
(AD)) of a split transcription factor (Licitra and Liu 1996, Henthorn et al. 2002, Baker et
al. 2003, Chidley et al. 2011, Odell et al. 2015). A bridging molecule, termed the
chemical inducer of dimerization (CID), containing methotrexate, linker, and a small
molecule of interest brings the bait/prey fusion proteins together in a functional ternary
complex, which can activate the expression of different reporter genes (Chapter 2 –
Figure 8A). We expressed the DBD of the GAL4 transcription factor as a fusion with
dihydrofolate reductase (DHFR), and the AD as a fusion with each isoform of T. gondii
CDC48. The CID, Mtx-MMV006169, was synthesized by our collaborators at the
University of St. Andrews (Drs. Fanny Tran and Nicholas Westwood) using the
previously described SAR analysis to determine the optimal position for linker
attachment (Chapter 2 – Figure 8B). CID competition assays show that MtxMMV006169 can enter yeast and compete for binding with a positive control CID
(Chapter 2 – Figure 9). Using this functional CID and the CDC48 fusion proteins, we
found no direct interaction between either isoform, suggesting that CDC48 is not the
target of MMV006169 in T. gondii (Chapter 2 – Figure 10 and 11).

2.4 Discussion
While the identification of lead compounds is of vital importance for drug
development, if the protein targets of these drugs are not fully understood the potential
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for unexplained side-effects increases. Since the parasite lytic cycle is necessary for
proliferation and viability, understanding the cellular machinery involved in growth is
vital to the development of more useful anti-parasitics. The MMV Open Access Malaria
box presented itself as a unique tool for the identification of potential anti-Toxoplasma
compounds since the compounds included in the Malaria box have already been shown to
inhibit erythrocyte-stage P. falciparum (Gamo et al. 2010, Guiguemde et al. 2010,
Meister et al. 2011, Spangenberg et al. 2013). Additionally, a number of the targets of
these molecules have already been characterized in other systems, helping to focus future
target identification efforts.
We have screened the 400 small molecules available in the MMV Open Access
Malaria box using a high-throughput YFP-based growth assay for inhibition of T. gondii
(Gubbels et al. 2003, Bessoff et al. 2014). Screening this collection at a single
concentration resulted in the identification of 79 potential inhibitors for further analysis.
This represents a 19.8% hit rate in our hands. Further examination of the synthetic
accessibility of these analogs and comparison of potencies against other apicomplexans
led us to focus on one compound, MMV006169. MMV006169 is a potent (1.15 µM)
inhibitor of T. gondii growth that we also showed inhibits both replication and invasion.
The compound contains a 2,4-diaminoquinazoline scaffold, and while MMV006169 has a
similar potency in T. gondii and C. parvum, other compounds containing this scaffold
were previously found have different potencies between the two organisms. It has been
suggested that these differences could be consequences of parasite divergence. For
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example, C. parvum lacks an apicoplast and thus uses different biochemical mechanisms
to generate isoprenoids than T. gondii (Bessoff et al. 2014).
Further structure activity relationship analyses confirmed the lack of correlation
between T. gondii and C. parvum IC50s for different analogs. However, these SAR
analyses provided further insight into how the molecule may be working in T. gondii.
Single modifications of R1 and R3 result in molecules sufficient to inhibit invasion and
replication, while these effects are lost if more than one modification of R1 is present.
Modifications to all three ring structures are not tolerated to maintain inhibition of
invasion and replication. Interestingly, preliminary invasion assays with additional
structural analogs suggest the substitution of methylamines to either end of the compound
(R3 on C-10 and R1 on C-2, data not shown) result in enhancement of invasion. This
suggests that the availability of the free, unhindered amine groups plays a role in
enhancement of invasion. This requires further analysis and confirmation using the more
sensitive laser-scanning cytometry method of quantifying parasite invasion (Mital et al.
2006). However, The presence of a conserved aromatic amine playing a role in the
enhancement of invasion was previously reported on a group of substituted
chloroisocoumarins (Child et al. 2013). Synthesis of an analog of these enhancers lacking
the amine resulted in lack of enhancement. These chloroisocoumarins were shown to
target TgPPT1, but lack of an impact on replication and structural differences led us to
believe that MMV006169 is likely working on another target. Another enhancer of
invasion found in a large-scale compound screen also contains an unhindered aromatic

50

amine (Carey et al. 2004). Further analysis of the role of this functional group on
enhancement of invasion is needed.
A compound containing the 2,4-diaminoquinazoline scaffold, was previously
presented as being a novel inhibitor of T. gondii motility, but not invasion (Kamau et al.
2012). This is an interesting phenotype since the machinery necessary for T. gondii
motility is also essential for parasite invasion. We resynthesized this molecule (Chapter 2
– Table 3, FT14.116.2) to look more critically at both processes. The assays used by
Kamau et al., were very general and only looked at changes in parasite trails and overall
invasion after one hour. There is a possibility that the parasites are actually moving, just
not in the canonical fashion observed by trail assays. We performed invasion assays using
two concentrations of compound (5 and 10 µM) and found an invasion defect at the
higher concentration of 10 µM (data not shown). Trail assays reveal that compound
treated parasites were still able to move (i.e., generate trails) comparable to those of the
DMSO control (data not shown). These discrepancies could be due to compound freeze
thaws or impure commercially provided compound in their hands.
We used the previously discussed SAR analyses to generate a CID for use in
yeast three-hybrid experiments. We chose EN01.065 (C-7) as the starting point for
synthesis and generated a CID capable of passing the yeast cell membrane as
demonstrated by CID competition assay. Using this CID, neither isoform of CDC48
induced the expression of reporter genes, suggesting there is no direct interaction
between CDC48 and MMV006169. However, there are some limitations to the yeast
three-hybrid system that may generate false negative results. First, the expression of T.
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gondii genes in yeast may result in misfolded proteins. If the protein is not in its native
confirmation, it will not interact with the small molecule correctly, and thus not induce
reporter genes. It is also possible that the T. gondii CDC48 proteins are not being made or
are being made and then degraded. Since the proteins have been cloned into the yeast
vector with an HA-tag, their presence can be tested by western blot. Localization of the
protein can also be examined using immunofluorescence. This would allow the
confirmation of the nuclear localization of the protein, but it will not confirm
functionality of the protein. If the protein is not functional, it may not be able to interact
with MMV006169 to produce reporter activation. To test the functionality of the T.
gondii isoforms in S. cerevisiae we could complement CDC48 deficient yeast with each
of the T. gondii isoforms. S. cerevisiae CDC48 mutants are characterized by the presence
of apoptotic markers and cell cycle arrest where large budded cells appear with the
nucleus located in the neck between the mother and the daughter cell (Moir et al. 1982,
Frohlich et al. 1991, Madeo et al. 1997). Should complementation rescue the cell cycle or
apoptotic phenotypes, and yeast three-hybrid experiments fail, then we would move on to
other target identification strategies for MMV006169. However, should complementation
experiments fail, we could only conclude that the isoforms do not function analogously to
that of yeast proteins in that specific environment. Confirmation of functionality would
then require the expression of these proteins recombinantly and testing for the ability for
the ATPase to function with more specifically designed assays.
Steric hindrance can also cause problems. In a yeast three-hybrid system prey
proteins are fused to a transcription factor. It could be that generating fusions with the
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amino terminus of each gene prevent proper small molecule binding. To counter this, the
transcription factor could be fused to the carboxy terminus instead. CDC48 is thought to
associate with Der1, a pore involved in the ERAD pathway (Agrawal et al. 2009). It is
possible that CDC48 needs to be associated with Der1 for proper folding to occur, and as
such will not occur in yeast. CDC48 orthologs are commonly transmembrane proteins,
but there is no evidence of transmembrane domains in either T. gondii isoform. Lastly,
addition of the methotrexate/linker portion of the CID to MMV006169 may preclude the
compound from properly interacting with its target. Further analyses of these possibilities
will be the subject of future studies. Nonetheless, this work has provided extensive SAR
analyses of MMV006169, which may contribute to future, lead compound development
and outlined the impact of a subset of analogs on invasion and replication.
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Chapter 2 – Table 1: Summary of MMV box hits against T. gondii
MMV box compounds found to inhibit T. gondii growth at 2.3 µM after two biological
replicates. Smiles, source data, set, and plate locations provided by MMV.

HEOS COMPOUND ID
MMV666601
MMV007564
MMV665917
MMV000563
MMV665891
MMV665909
MMV000653
MMV020439
MMV000570
MMV666105
MMV665977
MMV001246
MMV665915
MMV665798
MMV665935
MMV666596
MMV000642
MMV009060
MMV006309
MMV019758
MMV000498
MMV011944
MMV006937
MMV019064
MMV007160
MMV665827
MMV007907
MMV000788
MMV142383
MMV006861
MMV007839
MMV403679
MMV019670
MMV396669
MMV020654
MMV306025
MMV000963
MMV006319
MMV001318
MMV020660
MMV019266
MMV073843
MMV000445
MMV006882
MMV020403
MMV007127
MMV666123
MMV665886
MMV084434
MMV007577
MMV666109
MMV007020
MMV665936
MMV006656
MMV006522
MMV000720
MMV000619

Smiles

Source

Set

CCOC(=O)C1=C(N=C2SC(=Cc3cc(C)n(c3C)c4ccc(F)cc4)C(=O)N2C1c5cccc(OC)c5OC)c6ccccc6
GNF
Probe-like
Cc1ccc(Cn2c(nc3ccccc23)N4CCC(CC4)C(=O)NCc5cccs5)cc1
GNF;GSK
Drug-like
Clc1ccc(NC(=O)N2CCN(CC2)c3ccc4nncn4n3)cc1
GNF
Drug-like
COc1ccc(cc1)C2Sc3ccccc3N=C4C2=C(O)c5ccccc45
GNF
Drug-like
c1ccc(cc1)c2ccc(cc2)c3nc4ccccc4[nH]3
GSK
Drug-like
Brc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3
StJude
Drug-like
CCOc1ccccc1CNC(=O)C2C(N(CC(C)C)C(=O)c3ccccc23)c4cccs4
StJude
Drug-like
CCn1c(CN2CCN(Cc3ccccc3)CC2)nc4cc(NC(=O)c5cccs5)ccc14
GSK
Drug-like
CCc1ccc(Nc2cc(C)c3ccc(O)cc3n2)cc1
StJude
Probe-like
COCCN(C(C(=O)NCc1ccc(OC)cc1)c2ccc(cc2)C(C)C)C(=O)Cc3cccs3
GSK
Drug-like
CCOC(=O)C1=CN(CC)c2cc(N(C)CCc3ccc(OC)c(OC)c3)c(F)cc2C1=O
GNF;GSK
Probe-like
CSc1ccccc1C(=O)Nc2nc(cs2)c3ccccn3
StJude
Drug-like
COc1ccc(cc1)c2nc(NC(=O)CS(=O)(=O)c3ccc(F)cc3)sc2C
GNF;GSK
Drug-like
FC(F)(F)c1cccc(Nc2nc(nc3ncccc23)c4ccccc4)c1
GSK
Drug-like
FC(F)(F)c1ccc(Nc2nnnc3ccccc23)cc1
GNF;GSK
Drug-like
CSC1=NC(=Nc2c(C)cccc2C)C3(CCC(CC3)C(C)(C)C)N1c4ccc(Cl)cc4
GNF
Probe-like
COc1ccc(NC(=O)C2C(N(CC(C)C)C(=O)c3ccccc23)c4cccs4)cc1Cl
GNF;StJude Probe-like
CCN(CC)c1ccc(NC(=O)c2cccs2)cc1
GNF
Drug-like
CN(C)c1ccc(C=CC2=NC(=O)c3ccccc3O2)cc1
GNF;GSK;GNF Probe-like
COc1ccc(cc1OC)C(=O)Nc2ccc3nc(cc(C)c3c2)N4CCCCC4
GSK
Drug-like
CCN(CC)c1cc(C)c2cc(NC(=O)c3cccc(OC)c3)ccc2n1
StJude
Drug-like
n1c(NCCO)c2c(cccc2)nc1Nc3cccc(OC)c3
GNF;GSK
Drug-like
Cc1ccc(cc1)c2cc3nc4CCCCc4c(O)n3n2
GNF
Drug-like
COc1cccc(c1)c2nn(C)c3sc(cc23)C(=O)NCCN4CCN(CC4)c5ccccc5F
GSK
Drug-like
Cc1ccc(cc1)N2C3N(c4ccccc4C2N(c5ccccc35)S(=O)(=O)c6ccc(C)cc6)S(=O)(=O)c7ccc(C)cc7
GNF
Probe-like
CCOC(=O)C1=CN(CC)c2cc(N3CCCCC3)c(F)cc2C1=O
GNF;GSK
Probe-like
Cc1ccc(Nc2nc(cs2)c3ccccn3)cc1
GNF
Drug-like
CC(C)OCc1cc(CN2CCN(CC2)c3cccc(Cl)c3)c(O)c4ncccc14
StJude
Drug-like
CC(C)(C)c1ccc(cc1)C(=O)Nc2nc3ccccc3s2
StJude
Drug-like
C1CN(CCO1)c2ccc(Nc3ccnc4cc5ccccc5cc34)cc2
GNF
Probe-like
C1(O)(CC(=O)c(ccc(OC)c2)c2O1)C(F)(F)C(F)(F)F
GNF
Drug-like
c1(c(cnn1c2cccc(C)c2)C(=O)N3)N=C3n4nc(C)cc4NC(=O)c5cc(cccc6)c6o5
Commercial Drug-like
O=C(Nc1ccc(cc1)N2CCN(Cc3ccccc3)CC2)c4cccs4
GSK
Drug-like
n1c(cc(C)nc1Nc(cc2)ccc2NC(CCc3ccccc3)=O)N4CCCC4
Commercial Drug-like
CCC(O)c1ccc(Br)cc1NC(=O)c2cccc(Cl)c2
GSK
Drug-like
C1(=NC(N(C)C2=O)=O)C2=NC(=NN1CC)c3ccc(C(=O)OC)cc3
Commercial Drug-like
n1c(NCc2ccccc2)c3c(cccc3)nc1Nc(cc4)ccc4OC
GNF;StJude Drug-like
Cc1cc(Nc2cccc(F)c2)nc(NCc3ccccc3)n1
GNF
Drug-like
Clc1cccc(NC(=O)Nc2ccc(Br)cc2)c1
StJude
Drug-like
COc1ccc(cc1OC)c2nonc2NC(=O)c3cccc(Cl)c3
GSK
Drug-like
Cc1sc2ncnc(Sc3nc4ccccc4[nH]3)c2c1C
GSK
Drug-like
CN(C)c1ccc(cc1)N=Cc2ccc(cc2)N3CCOCC3
GNF
Probe-like
CCCCCCN1C(=N)N(CC(O)COc2cccc(C)c2)c3ccccc13
StJude
Probe-like
CCOC(=O)c1cnc2ccc(Cl)cc2c1NCCCN(C)C
GNF
Probe-like
COc1ccc(cc1)c2cn3c(C(=O)Nc4ccccc4Cl)c(c5CCCCn2c35)c6ccccc6
GSK
Probe-like
OC1=C2C(Sc3ccccc3N=C2c4ccccc14)c5ccc(Br)cc5
GNF
Probe-like
CC(C)(C)c1ccc(cc1)C(=O)Nc2c3CSCc3nn2c4cccc(Cl)c4
StJude
Probe-like
CC(Oc1ccc(NC(=O)c2cccs2)cc1)C(=O)c3ccc(Cl)cc3
GSK
Probe-like
COc1ccc(C=C2SC(=NC2=O)Nc3ccc(F)cc3)c(OC)c1
GNF;GNF;GNF Probe-like
Cc1ccccc1OCCSc2nc3ccc(NC(=O)c4ccccc4)cc3s2
GNF
Probe-like
CCOC(=O)C1(Cc2ccccc2)CCN(Cc3cccc(OC)c3O)CC1
StJude
Probe-like
CCOc1ccc2nc(C)cc(Nc3ccc(cc3)N(C)C)c2c1
GNF
Probe-like
Cc1ccc(cc1)S(=O)(=O)c2c(COC(=O)c3cccc(C)c3)c(nn2C)c4ccccc4
GNF
Probe-like
CCOC(=O)C1=CN(C)C=C(C1c2cc(Br)c(OCC)c(OC)c2)C(=O)OCC
GNF
Probe-like
CCOc1ccc2nc(C)cc(Nc3ccc(Br)cc3)c2c1
GNF
Probe-like
Cc1ccnc(NC(c2cccc(OCc3ccccc3)c2)c4ccc5cccnc5c4O)c1
GSK;StJude Probe-like
CCCCC(O)(C(CN1CCOCC1)c2ccc(Cl)cc2)c3ccc(Cl)cc3
StJude
Probe-like
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PLATE
WELL
PLATE
WELL
March2012 March2012 May2012 May2012
A
F07
A
A05
B
B10
B
A06
B
A03
B
A08
B
G08
B
A09
B
A08
B
B10
B
E02
B
B08
B
B11
B
B06
A
H08
A
B06
A
F08
A
B05
B
E06
B
B04
A
H02
A
C03
A
F09
A
C05
A
A02
A
C07
B
G03
B
D09
B
C02
B
D03
A
A07
A
D03
A
A09
A
E03
B
A09
B
E04
A
A08
A
E06
B
D09
B
E06
B
F09
B
E07
B
H11
B
F08
A
C05
A
F08
B
G09
B
F07
A
G07
A
F05
A
G03
A
G10
A
F06
A
H09
B
E10
B
H06
B
B09
B
H05
A
H06
A
H05
A
C10
A
H02
C
C08
C
A04
C
B06
C
A07
C
G09
C
H03
C
H02
C
D10
C
B08
C
D03
C
F11
C
E04
C
G11
C
E05
C
E05
C
E08
C
H03
C
E10
C
G02
C
F09
E
A06
E
A02
D
D09
D
A07
D
G08
D
A08
E
F05
E
A08
D
B08
D
A09
D
A03
D
A10
E
H03
E
A11
E
D07
E
B07
D
B11
D
B06
D
D05
D
C02
E
A09
E
C02
D
E02
D
C03
E
H07
E
C03
E
F11
E
C05
D
E08
D
C07
D
G10
D
C08

MMV000699
MMV000326
MMV007574
MMV665987
MMV006825
MMV008455
MMV007199
MMV396717
MMV665898
MMV000621
MMV019741
MMV007654
MMV666095
MMV396594
MMV666106
MMV396663
MMV007396
MMV000617
MMV011522
MMV007113
MMV667489
MMV006169

Cc1ccc(cc1)C2CC(n3nc(cc3N2)C(=O)N4CCN(CC4)C(c5ccccc5)c6ccccc6)C(F)(F)F
Cc1ccc2nc(C)cc(Nc3cccc(c3)C(F)(F)F)c2c1
O=C(Nc1ccc(cc1)C23CC4CC(CC(C4)(C2)c5ccccc5)C3)c6cccs6
CCCCCCc1cc(O)c2C3=C(CCC(C)C3)C(=O)Oc2c1
n1c(Nc(cc2)ccc2OC)cc(C)nc1NCc3ccccc3
COc1ccc(cc1)C2C(C(=O)Nc3cccc(OC)c3)c4ccccc4C(=O)N2C5CCCCC5
COc1ccccc1N2C(=N)SC(=Cc3ccc(OCc4ccccc4F)cc3)C2=O
c([nH]nc1c2c(O)cc(C)c(Cl)c2)(C3=O)c1C(c4ccccc4F)N3CCc(cc5)ccc5OC
COc1cc(cc(OC)c1OC)C(=O)Nc2ccc(cc2)c3nc4ccccc4[nH]3
CCCCCCC(O)(C(CN1CCOCC1)c2ccccc2)c3ccc(F)cc3
Cc1ccc(C)c(Cn2c(nc3ccccc23)N4CCC(CC4)C(=O)NCc5cccs5)c1
Cc1ccc(C)c(c1)c2csc(Nc3ccc(C)c(C)c3)n2
CCCc1c(C)nc2ccc(Br)cc2c1O
c12c(nc(c3ccc(OC)cc3)nc1N4CCN(C(=O)C5CCCCC5)CC4)sc(CCCC6)c26
O=C(NC1CCCCC1)C(N(CCc2ccccc2)C(=O)c3occc3)c4cccs4
c1(C(c(cccn2)c2)N3CCC(CC3)Cc4ccccc4)c(C)c(C)sc1NC(=O)c5ccco5
Cc1ccccc1OCCSc2nc3ccc(NC(=O)c4cccs4)cc3s2
COc1ccc(cc1)C(O)(CCC(C)C)C(CN2CCOCC2)c3ccc(Cl)cc3
Cc1ccc(Nc2nc(N)c3ccccc3n2)cc1Cl
c1ccc(cc1)C2=Nc3ccccc3N=C(c4ccccc4)c5ccccc25
N1C(c2cccc(cccc3)c23)C(CC=C4)C4c5c1c(Cl)ccc5C(OC)=O
C(Nc1nc(Nc2ccccc2)nc3ccccc13)c4ccccc4
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StJude
StJude
GNF
GNF
GNF
GNF
GNF;GNF
Commercial
GSK
StJude
GSK
GNF
GNF
Commercial
GSK
Commercial
GNF
StJude
GNF;StJude
GNF
Commercial
GNF

Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like
Probe-like

D
D
D
D
E
D
D
E
E
D
D
E
D
E
D
E
D
D
E
D
E
E

E07
C08
A07
C04
H11
H09
E09
E10
B03
H10
C10
A05
G05
F08
H05
B08
C11
F10
G10
G07
B10
E09

D
D
D
D
E
D
D
E
E
D
D
E
D
E
D
E
D
D
E
D
E
E

D09
D06
D05
D04
E05
E08
E09
E10
F09
F08
F06
F05
F03
F02
G03
G03
G06
G07
G11
H09
H03
B05

Chapter 2 – Table 2: Subset of MMV Malaria box molecules of interest
Five compounds chosen from the MMV Malaria box based on potency and similar
efficacies against C. parvum.

Name

Structure

IC 50 (μM) vs T. gondii (95% CI)

MMV000720

0.44 (0.30-0.66)

MMV403679

0.13 (0.11-0.14)

MMV001246

0.55 (0.44-0.70)

MMV000642

6.31 (4.25-9.36)

MMV006169

1.15 (0.74-1.79)
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Chapter 2 – Table 3: MMV006169 structural analogs
Seventy-four structural analogs of MMV006169 were ordered or synthesized (by Drs.
Fanny Tran and Nicholas Westwood at the University of St. Andrews), all containing a
conserved 2,4-diaminoquinazoline chemical scaffold. Calculated IC50 values for each
analog and corresponding 95% confidence intervals are reported. Excessively wide
confidence intervals are reported as “n/a”.
T. gondii IC 50 (µM)
(95% CI)

C. parvum IC 50
(µM) (95% CI)

MMV006169

1.15 (0.74-1.79)

1.5 (1.16-1.94)

FT14.116.2

0.26 (0.17-0.39)

2.83 (2.36-3.40)

EN01.068.2.3

0.44 (0.34-0.58)

4.09 (2.34-7.15)

EN01.042

0.46 (0.35-0.60)

0.87 (0.62-1.23)

OSSL_723641

0.55 (0.38-0.80)

0.44 (0.38-0.52)

Structure
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EN01.068.2.5

0.58 (0.31-1.09)

1.08 (0.64-1.80)

OSSL_324342

0.58 (0.46-0.75)

6.19 (2.80-13.69)

PA-Br

0.59 (0.16-2.19)

2.65 (2.30-3.05)

HG014

0.70 (0.25-1.94)

3.45 (3.10-3.84)

PA-01-22

0.74 (0.37-1.49)

>10 (n/a)

FT14.025.2

0.78 (0.52-1.17)

6.58 (4.63-9.36)

FT14.079.2

0.82 (0.34-1.99)

>10 (n/a)
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EN01.031

0.88 (0.32-2.41)

0.64 (0.48-0.87)

OSSL_324319

0.93 (0.71-1.20)

8.89 (6.35-12.45)

FT07.032.2

0.96 (0.80-1.16)

>10 (n/a)

CP01009

1.05 (0.58-1.91)

6.62 (6.08-7.22)

PA-01-09

1.06 (0.22-5.01)

5.82 (5.05-6.70)

FT07.031.7

1.01 (0.78-1.31)

>10 (n/a)

HG021

1.03 (0.78-1.36)

>10 (n/a)
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FT14.006.2

1.11 (0.74-1.68)

1.33 (1.00-1.76)

FT14.007.2

1.124 (0.70-1.80)

9.93 (n/a)

OSSL_723668

1.13 (0.57-2.25)

1.74 (1.29-2.39)

OSSL_723788

1.19 (0.89-1.60)

3.92 (1.25-12.32)

OSSL_102463

1.21 (0.81-1.80)

9.50 (n/a)

FT07.031.1

1.26 (1.08-1.47)

>10 (n/a)

EN01.065

1.27 (0.94-1.71)

0.37 (0.26-0.53)
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PA-01-20

1.33 (0.72-2.47)

5.35 (4.86-5.88)

OSSL_102470

1.34 (1.07-1.67)

0.93 (0.64-1.40)

OSSL_324373

1.42 (1.04-1.92)

4.73 (3.37-6.62)

OSSL_325124

1.43 (0.96-2.12)

5.50 (4.02-7.53)

OSSL_102466

1.45 (1.07-1.96)

5.60 (2.97-10.58)

FT07.031.6

1.45 (1.01-2.08)

1.03 (0.83-1.29)

FT14.084.1

1.59 (0.94-2.68)

4.63 (3.88-5.53)
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OSSL_723748

1.60 (0.90-2.84)

4.54 (3.23-6.36)

HG009

1.62 (1.13-2.32)

4.35 (3.92-4.83)

OSSL_102469

1.66 (1.29-2.14)

4.12 (1.62-10.47)

FT07.033.2

1.72 (1.55-1.91)

1.03 (0.18-6.08)

AP005

1.79 (0.68-4.71)

1.01 (0.77-1.32)

EN01.098

1.81 (1.34-2.45)

0.98 (0.85-1.14)

OSSL_102476

1.87 (1.55-2.26)

2.69 (1.66-4.37)
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EN01.096

1.97 (1.65-2.35)

1.37 (1.15-1.63)

CP01007

1.98 (1.40-2.80)

6.44 (6.06-6.84)

HG019

2.00 (1.48-2.72)

1.41 (1.13-1.75)

FT14.078.4

2.09 (1.78-2.44)

>10 (n/a)

OSSL_723692

2.12 (1.83-2.46)

0.93 (0.77-1.12)

AP002

2.24 (1.26-3.97)

0.46 (0.35-0.61)

HG015

2.31 (1.85-2.89)

2.74 (2.31-3.25)
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EN01.115

2.48 (1.68-3.67)

2.41 (2.13-2.72)

OSSL_324325

2.50 (1.63-3.86)

3.40 (1.97-5.85)

OSSL_324381

2.51 (2.07-3.04)

>10 (n/a)

EN01.134

2.55 (2.13-3.05)

1.45 (1.20-1.77)

AP003

2.56 (0.93-7.05)

0.69 (0.54-0.89)

PA-01-26

2.81 (n/a)

3.85 (3.31-4.47)

OSSL_324383

3.09 (2.49-3.83)

3.92 (2.64-5.80)
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EN01.131

3.10 (2.45-3.91)

0.34 (0.27-0.43)

OSSL_723780

3.22 (2.50-4.15)

1.15 (0.94-1.40)

OSSL_324318

3.30 (2.42-4.50)

4.24 (3.41-5.27)

OSSL_102478

3.33 (2.56-4.33)

1.25 (0.91-1.62)

OSSL_324399

3.36 (2.40-4.72)

1.99 (1.51-2.63)

OSSL_324316

3.69 (3.17-4.29)

>10 (n/a)

CP01004

3.94 (n/a)

4.48 (3.95-5.08)
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EN01.132

4.69 (4.03-5.46)

0.78 (0.67-0.91)

FT14.095.2

5.69 (3.89-8.33)

0.82 (0.65-1.03)

EN01.095

5.71 (3.95-8.25)

1.68 (1.51-1.87)

PA-01-21

5.96 (n/a)

4.31 (3.66-5.07)

FT14.026.2

6.57 (n/a)

2.33 (1.90-2.87)

OSSL_723607

7.28 (n/a)

>10 (n/a)

PA-01-11

11.54 (n/a)

8.12 (5.32-12.40)
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PA-01-12

>18.18 (n/a)

3.76 (3.16-4.47)

PA-01-27

>18.18 (n/a)

9.46 (8.68-10.30)

FT14.027.2

>18.18 (n/a)

>10 (n/a)

OSSL_324334

>18.18 (n/a)

>10 (n/a)

OSSL_324392

>18.18 (n/a)

>10 (n/a)

FT14.092.2

>18.18 (n/a)

0.69 (0.58-0.83)
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Chapter 2 – Table 4: SAR for phenotypic separation
Eleven structural analogs of MMV006169 were chosen based on similarities and
differences in potency between T. gondii and C. parvum and/or inclusion of major
modifications to the MMV006169 backbone. Analogs are listed from most to least potent
against T. gondii. INH=inhibitor, NE=no effect, PAR INH=partial inhibition.

Analog
Number
C-1
C-2
C-3
C-4
C-5
C-6
C-7
C-8
C-9
C-10
C-11

Compound

R1

MMV006169
H
OSSL_324342
3-CF 3
FT14.079.2
NHCH 3
EN01.031
H
FT07.032.2
3-CF 3
FT07.031.7 2-OMe, 3-CF 3
FT07.031.1 2-OMe, 3-CF 3
EN01.065
H
FT14.084.1 Cyclohexane
AP005
4-OMe
FT14.078.4
Ph
FT14.027.2
3-CF 3

R2

R3

H
H
H
H
H
H
H
H
H
H
H
8-OMe

H
H
CH2 Ph
3-OMe
4-OMe
H
4-OMe
2-OMe
NHCH(CH 3 ) 2
H
NHCH 3
4-OMe
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IC50 (μM)
T. gondii C. parvum
1.15
1.5
0.58
6.19
0.82
>10
0.88
0.64
0.96
>10
1.01
>10
1.26
>10
1.27
0.37
1.59
4.63
1.79
1.01
2.09
>10
>18.18
>10

Replication Invasion
INH

INH

INH
INH
INH
INH
INH
PAR INH
INH
INH
INH
PAR INH
NE

INH

NE
NE
INH

NE

Chapter 2 – Table 5: Primers for cloning T. gondii CDC48Ap and CDC48Cy
All primers were synthesized by Sigma Aldrich (The Woodlands, TX) with no special
modifications. Sequences homologous to pGADT7 are underlined and were used for
cloning in yeast.
Primer
1
2
3
4
5
6
7
8
9
10
11
12
13

Name
CDC48ApFw
CDC48ApRev
CDC48Ap480Fw
CDC48Ap978Fw
CDC48Ap1489Fw
CDC48Ap2007Fw
CDC48Ap2504Fw
CDC48CyFw
CDC48CyRev
CDC48Cy498Fwd
CDC48Cy1018Fwd
CDC48Cy1518Fwd
CDC48Cy2002Fwd

Sequence (5'è3'); Sequence homolgous to pGADT7 is underlined
GAGTACCCATACGACGTACCAGATTACGCTATGGGGACTGCGTGGTGCCC
ACAAGCCGACAACCTTGATTGGAGACTTGATCACTTTGTTTCCTTCGCCG
CGATCTATCGCACCCCAC
ATCAAAGTCACCCCACAG
GCGTATTGCTTCACGGTT
CAGCTCTGTCTGGAAGCC
AATGGACTCGATCGCGAA
GAGTACCCATACGACGTACCAGATTACGCTATGGCCGGCGGCATTCGCAG
ACAAGCCGACAACCTTGATTGGAGACTTGACTACGAGTAGAGGTCATCGT
CGTCCTGTAGAATTCAAG
TCCTTACCCTCATGGACG
TACCCTATCGACCATCCT
TTCTCCAGGCAACGTTGA
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150
100
50
0
1
-50

2

3

4

5

Days Post Infection

6

7

15.92µM
7.96µM
3.98µM
1.99µM
1.00µM
0.50µM
0.25µM
0.12µM
0.06µM
0.03µM
0.00µM

B

% Inhibition

Percent Positivity

A

150
100
50
0
-50

-1

0

1

2

log[MMV006169]µM

C

Chapter 2 – Figure 1: Effect of MMV006169 on T. gondii growth kinetics

A) YFP-based growth assay using varying concentrations of MMV006169. Values are
represented as percent positivity over time. The highest fluorescence reading obtained
during screening is assigned 100%, while blank wells containing cells and media are set
to 0%. All other values are assigned between those points. B) IC50 curve extrapolated
from YFP-based growth assay data. The concentration of MMV006169 necessary to
inhibit 50% of parasites is 1.15 µM (95% confidence interval: 0.74-1.79). Error bars
represent standard deviation (n=3). C) Structure of MMV006169 with 2,4diaminoquinazoline scaffold highlighted in red.
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Chapter 2 – Figure 2: MMV006169 is not toxic to HFFs

Viability of host cells was determined via ATPase assay. HFFs were exposed to
MMV006169 for 24-hours before host cell lysis and quantification of ATP levels by
luminescence. Luminescence is reported as relative luminescence units (RLU). All wells
were normalized to a control of HFFs and media with no CellTiter-Glo reagent. Sodium
azide was included to represent a “kill control” in which we know the cells are no longer
generating ATP. Bars represent mean +/- standard deviation, n=3. Data were analyzed
using a one-way ANOVA (***p≤0.001).
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Chapter 2 – Figure 3: MMV006169 inhibits T. gondii invasion and replication, not
motility.

Effect of MMV006169 on T. gondii invasion, motility, and replication. A) MMV006169
inhibits T. gondii invasion at 10 µM. Two color invasion assays were scored blindly by
immunofluorescence. (n=3, *p≤0.05 as determined by one-way ANOVA). B)
MMV006169 does not inhibit T. gondii motility. Parasite trails were stained with αSAG1 antibody and quantified by immunofluorescence (n=3, results analyzed by oneway ANOVA). C) MMV006169 inhibits T. gondii replication at 5 µM. HFFs were
infected with 2F1 YFP2 strain T. gondii and grown in the presence (red) or absence (blue)
of compound for 36 hours. The average number of parasites per vacuole in vacuoles
containing two or more parasites was determined by immunofluorescence (n=3, *p≤0.05,
**p ≤ 0.01, ***p ≤ 0.001, **** p ≤ 0.0001 as determined by two-way ANOVA).
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Chapter 2 – Figure 4: MMV006169 analogs are not toxic to host cells after 24
hours

Viability of host cells was determined via ATPase assay. HFFs were exposed to 10 µM of
each analog for 24-hours before host cell lysis and quantification of ATP levels by
luminescence. Luminescence is reported as relative luminescence units (RLU). All wells
were normalized to a control with no CellTiter-Glo reagent. Sodium azide was included
to represent a “kill control” in which we know the cells are no longer generating ATP.
Bars represent mean +/- standard deviation, n=3. Data were analyzed using a one-way
ANOVA (****p≤0.0001).
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Chapter 2 – Figure 5: Effect of MMV006169 structural analogs on replication

Quantification of T. gondii replication after 36 hours. Eleven compounds from the SAR
screen were assayed at 5 µM. The number of parasites per vacuole (in vacuoles
containing two or more parasites) was determined at each time point and compared to
DMSO-treated controls. (n=3; , *p≤0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 as
determined by two-way ANOVA).
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Chapter 2 – Figure 6: Effect of MMV006169 structural analogs on T. gondii
invasion

Quantification of the ability of T. gondii tachyzoites to invade HFFs. Five compounds
from the SAR screen were assayed at 10 µM and scored blindly by immunofluorescence.
(n=3; ****p ≤ 0.0001 as determined by one-way ANOVA).
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Chapter 2 – Figure 7: MMV006169 structural analogs cannot initiate replication

Quantification of the number of two-parasite containing vacuoles for analogs with the
most severe invasion defects. Replication assays were differentially stained for
intracellular and extracellular parasites at 36 hours using a standard two-color invasion
assay protocol. (n=3, 100 fields per coverslip).
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Chapter 2 – Figure 8: Targeted yeast three-hybrid and structure of MtxMMV006169

A) Schematic of targeted yeast three-hybrid ternary complex containing the DNAbinding (DBD) and activation domains (AD) of the GAL4 transcription factor (green)
and the CID. The CID is comprised of methotrexate (blue) fused to MMV006169 (red)
by a flexible linker (purple). The methotrexate moiety of the CID interacts with DHFR
and if MMV006169 interacts with either isoform of CDC48, reporter activation will
occur. B) Structure of MMV006169-based CID. Methotrexate is outlined in blue,
MMV0006169 in red, and the linker is found between the two.
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Chapter 2 – Figure 9: CID Competition Assay with Mtx-MMV006169

pGADCDPK1-containing yeast can activate reporter genes and grow in histidine lacking
media upon the addition of 25 µM CID7 (blue bars). The addition of 25 µM MtxMMV006169 to this functioning positive control (red bars) inhibited reporter activation.
This implies that Mtx-MMV006169 can enter yeast and compete for binding with CID7.
Bars represent mean +/- standard deviation; n=2. Data were analyzed using paired t-tests
(**p≤0.01, ****p≤0.0001).
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Chapter 2 – Figure 10: Targeted yeast three-hybrid liquid growth assay suggests
MMV006169 does not interact with CDC48Ap.

Growth of yeast in media lacking histidine is a reflection of reporter activation. The
positive control, CDPK1, is able to grow more robustly in the presence of CID7 than in
DMSO (red versus blue bars), implying a direct interaction between the CID and
CDPK1. CDC48Ap grows to the same level in the presence of Mtx-MMV006169
(purple) and DMSO (green), meaning the histidine reporter gene has not been activated.
Bars represent mean +/- standard deviation; n=3. Data were analyzed using paired t-tests
(*p≤0.05, **p≤0.01).
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Chapter 2 – Figure 11: Targeted yeast three-hybrid liquid growth assay suggests
MMV006169 does not interact with CDC48Cy.

Growth of yeast in media lacking histidine is a reflection of reporter activation. The
positive control, pGADCDPK1, is able to grow more robustly in the presence of CID7
than in DMSO (red versus blue bars), implying a direct interaction between the CID and
CDPK1. pGADCDC48Cy grows to a similar level in the presence of Mtx-MMV006169
and DMSO (green and purple bars), meaning the histidine reporter gene has not been
activated. Bars represent mean +/- standard deviation; n=3. Data were analyzed using
paired t-tests (*p≤0.05, **p≤0.01).
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CHAPTER 3: APPROACHES TO IDENTIFYING THE TARGET(S) OF
MMV006169

3.1 Introduction
Studies aimed at identifying the target of small molecules face a variety of
challenges. 1) Is the putative target identified the biologically relevant target? 2) Does the
molecule have multiple targets? 3) Is the compound working through the organism of
interest or through environmental/host cell mechanisms? To ensure these questions are
answered adequately, multiple strategies for target identification are commonly used in
parallel. Recent advances in high-throughput screening (Farrell et al. 2012), CID
development (Tran et al. 2013), and the CRISPR/Cas9 system for gene deletions (Shen et
al. 2014, Sidik et al. 2014, Sidik et al. 2016) have assuaged the process of target
confirmation.
Full genome mutagenesis-based approaches for initial target identification have
been successful in the study of T. gondii using several mutagens (Pfefferkorn and
Pfefferkorn 1979, Morrissette et al. 2004, Gubbels et al. 2008, Coleman and Gubbels
2012, Farrell et al. 2014) and have led to the isolation of mutants resistant to varying
levels of compound. However, if the target of these molecules is essential, the resistant
mutants often have mutations in drug transporters, which render the parasite resistant
without providing direct target information. This approach is also less informative if the
compound has more than one target, as one may not be able to distinguish between partial
compound resistance in phenotypic assays.
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We have recently shown that a yeast three-hybrid approach to target
identification can be useful for probing the T. gondii genome (Odell et al. 2015). Yeast
three-hybrid has the advantage of examining protein-small molecule interactions without
directly inhibiting the parasite life cycle. The interaction is first identified in yeast, and
can then be brought back into the parasite for target confirmation. This approach is
beneficial in that it allows one to look at essential genes and to identify more than one
target at a time.
Here, we present approaches towards the identification of target(s) of the
Medicines for Malaria Venture compound MMV006169. We have previously shown that
MMV006169 inhibits the growth of both T. gondii and C. parvum (Bessoff et al. 2014),
and specifically reduces T. gondii invasion and replication, with no effect on motility
(Chapter 2). We examined the possibility of MMV006169 interacting with TgCDC48Cy
or TgCDC48Ap based on structural similarities between MMV006169 and a known p97
inhibitor (Chapter 2) (Chou et al. 2011). Targeted yeast three-hybrid experiments to
determine if MMV006169 could interact with TgCDC48Cy or TgCDC48Ap came up
negative, suggesting the compound is working through an interaction with a different
parasite and/or host cell protein target. The work in this chapter describes whole genome
mutagenesis attempts to generate parasites resistant to MMV006169 and its analogs.
Yeast three-hybrid library screens are performed identifying a putative host cell protein
target for MMV006169, whose T. gondii isoforms show no interaction with
MMV006169 by targeted yeast three-hybrid.
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3.2 Materials and Methods
3.2.1 Parasite culture
T. gondii RH ΔhxgprtΔku80 and 2F1 YFP2 tachyzoites (Gubbels et al. 2003),
kindly provided by Dr. Marc-Jan Gubbels, were passaged serially in confluent
monolayers of human foreskin fibroblasts (HFFs) maintained at 37°C (5% CO2 and
constant humidity) in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented
with 10mM HEPES, pH 7.2, 10 units/mL penicillin G sodium salt, 10 units/mL
streptomycin sulfate, and containing 1% heat-inactivated fetal bovine serum as
previously described (Roos et al. 1994).

3.2.2 N-ethyl-N-nitrosourea titration and plaque assay
Titration of N-ethyl-N-nitrosourea (ENU) was performed as previously
described with the following modifications (Coleman and Gubbels 2012, Farrell et al.
2014). Upon fresh lysis, 1 mL of 2F1 YFP2 tachyzoite were plated on a confluent T25
tissue culture flask of HFFs and incubated at 37°C for 24 hours in Ed1 medium. Medium
was replaced with 10 mL of Ed1 diluted (1:10) in DMEM and incubated at 37°C for 10
minutes. ENU was added in 0, 14.6, 29.3, 58.6, or 117 µL volumes (0.85M stock in
DMSO) per flask (working dilutions of ENU will be 1.25, 2.5, 5, and 10 mM,
respectively) and DMSO such that total is 117 µL for each flask. Flasks were incubated
for 4 hours in at 37 °C and then washed with cold sterile PBS before harvesting by
syringe release, passage through a 3-µm Nuclepore filter (Whatman, Piscataway, NJ), and
gently pelleting for 4 minutes at 1,100 x g. 10,000 parasites in 3 mL of Ed1 media were
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added to one well in a 6-well plate. Parasites were serially diluted 10-fold across the
remaining wells. Plates were incubated at 37°C for 7 days to allow plaques to form. After
incubation, medium was aspirated and cell monolayers were fixed with 100% ethanol.
Monolayers were stained using crystal violet solution containing 2% w/v crystal violet
and 0.8% w/v oxaloacetate in ethanol, washed with PBS, and then air dried at room
temperature.

3.2.3 ENU mutagenesis
Mutagenesis was performed as previously described with a few modifications
(Coleman and Gubbels 2012, Farrell et al. 2014). One milliliter of freshly lysed 2F1
YFP2 parasites (in Ed1 media) were seeded onto a confluent monolayer of HFFs in a T25
tissue culture flask and incubated at 37°C for 24 hours. Medium was replaced with 10
mL of Ed1 diluted 1:10 in DMEM and placed at 37°C for 10 minutes. Flasks were treated
with 72.7 µL ENU (100 mg/mL stock in DMSO) for 4 hours at 37°C. Each flask was
washed three times with cold filter sterilized PBS. Monolayers were harvested by syringe
release, passed through a 3-µm Nuclepore filter (Whatman, Piscataway, NJ) to eliminate
host cell debris, and gently pelleted (1,100 x g) for 4 minutes. The entire pellet was added
to a single T25 tissue culture flask and allowed to lyse naturally. Mutagenized parasites
were then passaged in media containing the EC90 of each compound of interest.

3.2.4 Compound-induced cyst staining
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HFFs were grown to confluence on 12 mm circular coverslips in 12-well plates.
MMV006169 resistant parasites were harvested by syringe release, passed through a 3µm Nuclepore filter (Whatman, Piscataway, NJ) to eliminate host cell debris, and gently
pelleted (1,100 x g, 4 minutes). Parasites were added to each coverslip at a multiplicity of
infection of 4x105 in the presence of 3 µM MMV006169. After 7 days, coverslips were
incubated in fixative solution (1X PBS + 4% v/v paraformaldehyde) for 20 minutes,
permeabilized (1X PBS + 0.25% v/v Triton X-100) for 15 minutes, and blocked for 30
minutes in 1X PBS + 1% w/v bovine serum albumin. Coverslips were incubated for 30
minutes in rabbit polyclonal anti-Toxoplasma (1:2000, catalog #90700556; AbD Serotec,
Raleigh, NC) and then with goat anti-rabbit IgG conjugated to Alexa 488 (Invitrogen,
2mg/mL) at a 1:500 dilution together with TRITC-conjugated Dolichos biflorus lectin
(Sigma-Aldrich, St. Louis MO) at a dilution of 1:100 for 60 min. 2F1 YFP2 parasites
treated with DMSO for 24 hours were included as a control. Coverslips were sealed to the
surface of glass slides using nail polish and visualized at 100X on a Nikon Eclipse TE300
epifluorescence microscope.

3.2.5 YFP-based growth assay
Growth of T. gondii strain 2F1 YFP2 parasites was monitored as described
previously (Gubbels et al. 2003) with several modifications. Both parasites and HFFs
were continuously cultured in HyClone DMEM/high modified medium without phenol
red (Thermo Fisher Scientific) containing 1 or 10% v/v heat-inactivated fetal bovine
serum (FBS). Medium was supplemented with 10 units/mL penicillin G sodium salt, 10
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units/mL streptomycin sulfate, 10 mM HEPES, pH 7.2. Special Optics black/clear 384well tissue culture-treated plate (BD Falcon) were seeded with 5x103 HFFs (in 50 µL
medium containing 10% v/v FBS) and grown at 37°C (5% CO2 with constant humidity).
Upon confluence, wells were washed with culture medium containing 1% v/v FBS.
Thirty microliters of culture medium containing 1% v/v FBS was added to each well. 2F1
YFP2 tachyzoites were syringe released, passed through a 3-µm Nuclepore filter
(Whatman, Piscataway, NJ), and gently pelleted (1,100 x g) for 4 minutes. Parasites were
resuspended in culture medium supplemented with 1% v/v FBS and diluted to 1x105
parasites/mL. Twenty microliters of medium containing 2,000 parasites was added to
each test well. Serially diluted test compounds were added to each well in a 5 µL volume.
Plates were incubated at 37°C in 5% CO2 (constant humidity) and fluorescence was read
daily for 8 days from the bottom of the plate with the lid in place using a Synergy 2
microplate reader (BioTek, Winooski, VT; excitation 485/20 and emission 528/20).
Pyrimethamine was included as a positive control in each plate. The IC50 of each
compound was determined as described previously (Bessoff et al. 2014).

3.2.6 cDNA library preparation and negative selection
A previously generated T. gondii oligo-dT primed cDNA library containing
2.4x106 total CFU with an average insert size of 1.65 kb in the vector pGADT7
(generously provided by Dr. Michael White, University of South Florida) and the vector
pGBKeDHFR was used to transform competent BAPJ69-4A yeast cells as described
(Kvaal et al. 2002, Baker et al. 2003, Clontech 2007, Shaffer et al. 2012). The resulting
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transformed yeast culture was plated on 50 x 150 mm diameter yeast drop out media
plates containing 2% w/v glucose and lacking leucine and tryptophan (SC +Glu –trp –
leu) and incubated at 30°C for 5 days. Plates were then placed at 4°C overnight to harden
the media. Transformants were pooled by flooding each plate with 3 mL 1xTE buffer and
scraped with a rubber policeman. All yeast was pooled, resuspended in glycerol solution,
and frozen in aliquots containing 4.35x107 CFU/mL.
Negative selection was performed on a freshly thawed aliquot of pretransformed yeast (containing library and pGBKeDHFR) by plating it on 20 x 150 mm
plates of drop out media (SC +Glu –trp –leu) containing 0.5 g/L 5-fluoroorotic acid (5FOA, Zymo Research) similar to that previously described (Chidley et al. 2011). The
surviving yeast transformants were pooled and aliquoted at 2x107 CFU/mL. A single
aliquot of yeast is thawed for each library screen.

3.2.7 Titering 3-Amino-1, 2, 4-triazole (3-AT) for library screens
A 5M solution of 3-AT (MP Biomedicals) was two-fold serially diluted and
plated (SC +Glu –trp –leu) such that final concentrations of 5 mM, 2.5 mM, 1.25 mM,
0.63 mM, and 0.31 mM were obtained. The positive control CID7 (or DMSO) was spread
onto each plate at a final concentration of 5 µM. Plates were allowed to incubate at room
temperature overnight in the dark. Library containing yeast was then plated at 7x107
CFU/mL and incubated at 30°C for 7 days. Colonies on each plate were marked and
recorded daily until a lawn was seen on plates containing CID7 with no 3-AT. The
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concentration of 3-AT in which no growth was seen on DMSO control plates, but was
seen upon CID treatment was used in all future experiments.

3.2.8 Yeast three-hybrid library screens
On the day prior to each library screen, CID was spread onto yeast drop out
media containing 2% w/v glucose selective for the cDNA library (leucine), DNA-binding
domain (pGBKeDHFR, tryptophan), and the histidine reporter gene (SC +Glu –trp –leu –
his) at a chosen concentration (25 mM for Mtx-MMV006169). 3-AT was also spread on
each plate at a final concentration of 1.25 mM. These plates were left at room
temperature overnight to allow the CID and compound to absorb into the yeast media. A
negative control plate was set up in parallel containing DMSO in place of CID. A library
aliquot was removed from -80°C, diluted, counted, and plated at 5x107 CFU/mL (20x
library coverage). Plates were incubated at 30°C and monitored daily until growth was
seen on negative control (DMSO + 3-AT) plates.

3.2.9 Yeast three-hybrid reporter confirmation
Confirmation of reporter gene activation was done similarly to that previously
published with several modifications (Odell et al. 2015). A single colony of yeast isolated
from a yeast three-hybrid library screen was used to inoculate 3 mL of synthetic complete
media supplemented with glucose lacking tryptophan and leucine (SC +Glu –trp –leu)
and incubated with shaking for 48 hours. On the day of the assay, 200 µL of yeast was
sub-cultured into 4 mL of SC +Glu –trp –leu and incubated for 4 hours until the yeast
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reached log phase. The yeast was counted and diluted to 2x105 cells/mL and 25 µL was
used to inoculate the wells of a 96-well plate (BD Falcon) containing 125 µL SC +Glu –
trp –leu –his. Wells were also treated with 1.5 µL of 2.5 mM CID (or DMSO) and 1.5 µL
of 50 mM 3-AT to reduce background growth. Media alone (150 µL) with 1.5 µL DMSO
and 1.5 µL 3-AT were included as negative control. A positive control including 125 µL
media, 1.5 µL 2.5 mM CID7, 1.5 µL 50 mM 3-AT, and 25 µL (2x105) yeast expressing
pGBKeDHFR and pGADBRADIN were included in each assay plate. Plates were
parafilmed and incubated with shaking (200 rpm). The OD600 for each well was recorded
daily from the bottom of the plate with the lid in place using a Synergy 2 microplate
reader (BioTek, Winooski, VT). The assay was terminated with robust growth was
observed in positive control wells.

3.2.10 Construction of pGADNDH2-1 and pGADNDH2-2
Plasmid construction was completed using restriction enzymes and Phusion high
fidelity polymerase purchased from New England BioLabs (Ipswitch, MA). All primers
were synthesized by Sigma Aldrich (The Woodlands, TX). To construct pGADNDH2-1,
pGADT7 (Clontech Laboratories, Mountain View, CA), was digested with SacI and
NdeI. TgNDH2-1 was amplified from RH ΔhxgprtΔku80 cDNA using primers 14 and 15
(Chapter 3 – Table 3). Gel extracted digested plasmid and the TgNDH2-1 PCR product
were co-transformed into competent AH109 yeast as previously described (Gietz and
Schiestl 2007). Transformants were selected on yeast drop out plates (SC +Glu –leu) and
incubated at 30°C for 48 hours. The resulting plasmid was screened by restriction digest
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and sequenced using primers 16 and 17 (Chapter 3 – Table 3). pGADNDH2-2 was
cloned as described above using primers 18-22.

3.2.11 Targeted yeast three-hybrid liquid assay
To perform targeted yeast three-hybrid assays a plasmid containing the
hypothesized MMV006169 target (pGADNDH2-1 or pGADNDH2-2) and a plasmid
encoding E. coli dihydrofolate reductase fused to the Gal4 DNA-binding domain
(pGBKeDHFR) was co-transformed into competent BAPJ69-4A yeast cells (a generous
gift from Dr. Donald Doyle, Georgia Institute of Technology), plated on yeast drop out
plates (SC +Glu –trp –leu) and grown at 30°C. A single colony of the resulting cotransformants was grown overnight in 3 mL of synthetic complete liquid media (SC +Glu
–trp –leu). After 24 hours, 200 µL of the yeast culture was used to inoculate 4 mL of SC
+Glu –trp –leu and incubated for 4 hours with shaking (200 rpm). Log phase cells
(determined by OD600) were counted and diluted to 2x105 cells/mL. 25 µL was used to
inoculate each test well in a 96-well plate (BD Falcon) containing 125 µL SC +Glu –trp –
leu –his. CID (1.5 µL of 2.5 mM or DMSO) and 3-AT (1.5 µL of 50 mM) were added to
test wells. As a negative control, 1.5 µL DMSO and 1.5 µL 3-AT were added to well
containing 150 µL of media alone. BAPJ69-4A strain yeast expressing pGBKeDHFR and
a plasmid encoding the Gal4 activation domain fused to TgBRADIN (Odell et al. 2015)
were used as a positive control (125 µL media, 1.5 µL 2.5 mM CID7, 1.5 µL 50 mM 3AT, and 25 µL yeast). Plates were sealed with parafilm and incubated with shaking (200
rpm) at 30°C. With the lid in place, the OD600 for each well was recorded from the
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bottom of the plate using a Synergy 2 microplate reader (BioTek, Winooski, VT). Plates
were read daily and the assay was terminated when robust growth was observed in
positive control wells.

3.3 Results
3.3.1 Isolation of MMV006169 resistant mutants
In an attempt to identify the target(s) of MMV006169, we implemented a whole
genome mutagenesis approach that has previously proven successful in the study of T.
gondii (Pfefferkorn and Pfefferkorn 1979, Morrissette et al. 2004, Gubbels et al. 2008,
Coleman and Gubbels 2012, Farrell et al. 2014). We used N-ethyl-N-nitrosourea (ENU),
a DNA alkylating agent, which works primarily by nucleotide substitution with a
preference for A-T to T-A transversions or A-T to G-C transitions (Acevedo-Arozena et
al. 2008, Farrell et al. 2014). This approach allows us to interrogate the entire genome,
including essential genes, which is not possible using other deletion or gene interruptionbased techniques. It was previously shown that by inducing 70% killing of parasites, one
could generate a parasite line with 10-100 mutations per genome (Pfefferkorn and
Pfefferkorn 1979, Farrell et al. 2014). Since ENU is unstable in liquid stocks, we began
by titering and pre-aliquoting our mutagen to avoid further freeze thaw cycles. By
exposing parasites to varying concentrations of mutagen and performing plaque assays on
each population, we determined that treating parasites at a final concentration of 6.31
mM of ENU was adequate to induce 70% killing (Chapter 3 – Figure 1).
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Using this concentration of mutagen we performed upwards of 20 attempts to
generate parasite lines resistant to the parent compound (MMV006169), OSSL_324342
(IC50=0.58 µM), OSSL_732641 (IC50=0.55 µM), and with OSSL_324373 (DBeQ,
IC50=1.42 µM) (Chapter 2 – Table 3). These analogs were chosen based on potency.
Despite changing the mutagenesis protocol, varying compound concentrations, and longterm culturing in compound, we were unable to generate resistant parasite lines to any
compound other than MMV006169. We isolated nine clones with some level of
resistance to MMV006169, and saw a maximum shift in IC50 of 3.6-fold above the nonmutagenized control (Clone 3, 4.41 µM, Chapter 3 – Table 1). However, we noted that
these resistant parasites were never able to naturally egress from host cells. Instead, they
stained positively with Dolichos biflorus lectin indicative of tissue cyst formation
(Chapter 3 – Figure 2). This suggests that prolonged exposure to compound or the
mutations created during ENU exposure resulted in differentiation into bradyzoites.
Based on the lack of a robust shift in IC50 and the knowledge that other groups have been
unable to isolate resistant mutants against related analogs (Jon Boyle, personal
correspondence), we decided to implement an alternate strategy for target identification.

3.3.2 Yeast three-hybrid system optimization
As an alternate approach to identifying the target(s) of MMV006169, we
performed library-scale yeast three-hybrid experiments to examine its target profile. As
false-positives are a common constraint in yeast three-hybrid experiments, we
implemented a negative selection step to minimize these interactions (Chapter 1 – Figure
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5). We used the yeast strain BAPJ69-4A, which was generated such that the reporter
URA3 was inserted into the HO locus under the control of a GAL4 inducible promoter,
and media containing 5-fluoroorotic acid (5-FOA) for this selection (Chidley et al. 2011,
Shaffer et al. 2012). In yeast without functional URA3, which encodes OMP
decarboxylase, 5-FOA is converted to 5-fluorooritidine monophosphate (5-FOMP),
which is not harmful to the cell. However, in the presence of functional OMP
decarboxylase, 5-FOMP is converted to 5-fluorouridine monophosphate, a competitive
inhibitor of thymidylate synthase, and is thus toxic to the cell. This means that anything
expressing URA3 in the absence of a functional transcription factor will be killed. Yeast
that survives this selection is pooled and used in conjunction with CID to perform our
full-scale library screens.
Titering of 3-amino-1, 2, 4-triazole (3-AT) also proved important in our library
screens. 3-AT is a competitive inhibitor of the HIS3 gene, which encodes
imidazoleglycerol-phosphate dehydratase. The HIS3 reporter has been shown to be leaky,
meaning that low levels of the gene product are expressed in the absence of CID (Van
Criekinge and Beyaert 1999). To counter this leakiness, 3-AT can be added to kill
anything expressing low levels of HIS3 (Durfee et al. 1993, Fields 1993, Clontech 2007).
We spread concentrations of 3-AT ranging from 0.31 µM – 5 µM and either DMSO or a
positive control CID7 onto each plate. Library-containing yeast was then plated and the
number of yeast colonies present on each plate was recorded daily for seven days
(Chapter 3 – Table 2). We chose to use 3-AT at 1.25 µM, which inhibited background
growth (DMSO plates) but allowed growth of yeast in the presence of CID.
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3.3.3 A host cell target for MMV006169
Screening of the negatively selected cDNA library with Mtx-MMV006169
presented 18 clones encoding a potential CID-interacting protein. Each clone was
analyzed in a reporter activation assay, where yeast growth is dependent on its ability to
synthesize histidine. We isolated a single clone (#14) capable of growing robustly in
media lacking histidine (Chapter 3 – Figure 3). Sequencing analysis revealed that this
clone contained the C-terminal 867 base pairs of the gene encoding human NADH
dehydrogenase subunit 2 (ND2; accession: P03891). ND2 is a component of complex 1
of the electron transport chain, which plays a role in oxidation of NADH to NAD, proton
pumping, and the shuttling of electrons to ubiquinone (Kerscher et al. 2008). It has been
previously shown that both quinolones and quinazolines can inhibit complex 1 function,
but inhibition is typically toxic to the host cell (Degli Esposti 1998, Li et al. 2003). Our
initial analysis of toxicity at 24 hours showed no evidence of host cell toxicity (Chapter 2
– Figure 4), however, upon extension of our toxicity analysis we found EN01.065 is toxic
to host cells after longer periods of exposure (Chapter 3 – Figure 4). This suggests that
EN01.065 may be working by inhibiting ATP production.
In contrast to the proton-pumping NADH dehydrogenase (complex 1) found in
mammalian cells, T. gondii has 2 isoforms of type II, non-proton pumping NADH
dehydrogenases (TgNDH2-1 and TgNDH2-2) (Saleh et al. 2007). It has been previously
shown that HDQ, a quinolone, can directly inhibit TgNDH2-1 resulting in a defect in
parasite replication (Lin et al. 2008). Since it is known that both quinolones and
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quinazolines can inhibit mammalian complex I, we hypothesized that quinazolines may
also be able to inhibit T. gondii NADH dehydrogenases. To test this, we cloned both
isoforms (TgNDH2-1 and TgNDH2-2) into our yeast expression vectors and performed
targeted yeast three-hybrid experiments using Mtx-MMV006169. Neither isoform
resulted in reporter activation in this system, suggesting that MMV006169 does not
interact with TgNDH2-1 or TgNDH2-2, but may actually be working through host cell
ND2 (Chapter 3 – Figure 5).

3.4 Discussion
Small molecule target identification has been performed using a broad range of
approaches, including affinity chromatography, phage-display libraries, whole genome
mutagenesis, and yeast three-hybrid experiments (see Chapter 1 for comprehensive
review). We recently screened the Medicines for Malaria Venture Open Access Malaria
box (Chapter 2) (Bessoff et al. 2014). In that work, we show that MMV006169 is a
potent inhibitor of T. gondii growth, more specifically invasion and replication. In this
study, we present the results of T. gondii whole genome mutagenesis to attempt to
identify the target(s) of MMV006169. We attempted to generate mutants against
MMV006169 and three structural analogs (OSSL_324342, OSSL_732641, and
OSSL_324373), both at the IC50 and EC90 of each compound as determined by YFPbased growth assay (see Chapter 2 for further detail). We were only able to generate
mutants resistant to MMV006169 at its EC90 (3.2 µM). Of the 9 clones isolated, only a
maximum of 3.6-fold increase in the IC50 of MMV006169 was observed. Previous work
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with other compounds has shown that resistance is not always associated with large
changes in the IC50. For example, Morrissette et al. isolated several different mutations in
α-tubulin that conferred oryzalin resistance, but were associated with different changes in
the IC50 (2 µM or 25 µM) compared with the original IC50 of oryzalin (Morrissette et al.
2004). The same phenomenon was reported by Nagamune et al. who saw a 2 to 3-fold
increases in the IC50 of artemisinin in resistant parasites compared to wild-type
(Nagamune et al. 2007). However, the fact that we also could not generate mutants
resistant to additional structural analogs, and the failure of other labs to do so (Jon Boyle,
personal correspondance), led us to suspect that the molecule has more than one parasite
target or it is working exclusively on host cells. The former hypothesis is supported by
the fact that structural analogs of MMV006169 show varying effects on T. gondii
invasion and replication (Chapter 2). Additionally, work on a related analog
(resynthesized and screened as FT14.116.2, Chapter 2 – Table 3) shows C5 inhibits T.
gondii motility, but not invasion (Kamau et al. 2012), further suggesting the likelihood of
the analogs hitting multiple targets.
In this chapter, we presented preliminary data suggesting that an MMV006169resistant parasite line differentiates into bradyzoites when grown in the presence of
compound. Since the genome of these parasites was never sequenced, we cannot confirm
that they contained any point mutations rendering them truly resistant. This implies that
treating tachyzoites with MMV006169 for prolonged periods of time results in their
differentiation to bradyzoites. It is known that parasites will undergo differentiation as
part of a stress repsonse when exposed to different pharmacological and physical triggers
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(Sullivan and Jeffers 2012). Interestingly, it has also been shown that bradyzoites
continue to replicate within tissue cysts at a rate much slower than tachyzoites (Watts et
al. 2015). This led us to wonder if the parasites quantified in our replication assays were,
in fact, bradyzoites and not tachyzoites. To test for a heightened stress reponse we can
expose parasites to media of varying alkalinity (7.2-8.2) and look for differences in their
ability to differentiate (Hong et al. 2016). If MMV006169 does cause a heightened stress
response, compound exposure at pH 8.2 will result in a greater level of differentiation
compared to untreated parasites. The same may hold true for lower pH (7.4 or 7.8) media,
which doesn’t normally stimulate differentiation of wild-type parasites. Determination of
the exact step in which stage conversion occurs will be the subject of future studies.
In an attempt to identify the target(s) of MMV006169, we implemented a yeast
three-hybrid approach, with which we have been successful in the past (Odell et al.
2015). Our screening attempts suggest that MMV006169 may function by inhibiting
human NADH dehydrogenase subunit 2 (ND2), a critical part of complex 1 of the
electron transport chain. Complex 1 is comprised of 46 different subunits, 7 of which
(ND1-6 and ND4L) are mitochondrially encoded (Chomyn et al. 1985, Attardi et al.
1986, Chomyn et al. 1986, Voet et al. 2008). The complex is divided into three functional
units, a dehydrogenase, hydrogenase-like, and transport unit (Friedrich and Scheide 2000,
Mathiesen and Hagerhall 2002). ND2 is part of the dehydrogenase unit, responsible for
oxidizing NADH to NAD. ND2 is also thought to be necessary for proper complex 1
assembly (Ugalde et al. 2007). ND2 is comprised of 9 transmenbrane domains, 5 of
which were present in the fragment recovered in our yeast three-hybrid screen. Typically,
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transmembrane domain containing proteins are not recovered in yeast three-hybrid
screens as they must be present in the yeast nucleus for an interaction to occur. However,
since we are expressing only a fragment of a human gene in yeast, we cannot eliminate
the possibility that the protein is misfolding or not being properly trafficked. The
misfolded/improperly trafficked protein would be retained in the endoplasmic reticulum,
and since the endoplasmic reticulum is contiguous with the nucleus these proteins could
still interact with a CID.
Over 60 different compound families have been shown to inhibit complex 1.
They are divided into three different classes: A) quinones, B) semiquinones, and C)
quinols (Degli Esposti 1998). Interestingly, no specific binding sites have been defined
for these compound classes; they are all believed to bind the same hydrophobic pocket
(Okun et al. 1999). MMV006169 contains a 2,4-diaminoquinazoline scaffold, which
belongs with the class B inhibitors of ND2. Interesting, Mtx-MMV006169 was designed
using EN01.065, an analog differing from the parent only in the addition of a methoxy
group, as a starting point. EN01.065 shows the most dramatic impact on host cell ATP
levels after 8 days, which further strengthens the hypothesis that MMV006169 analogs
may work by inhibiting host cell enzymes.
T. gondii isoforms of ND2 (TgNDH2-1 and TgNDH2-1) are considered
alternative type II dehydrogenases. Their active sites face the mitochondrial matrix and
they are individually non-essential (Lin et al. 2011). Like P. falciparum and most other
type II NADH dehydrogenases, TgNDH2-1 and 2-2 are thought to interact with
membranes through the aid of amphipathic α-helices, but possess no transmembrane
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domains (Melo et al. 2004, Fisher et al. 2007, Lin et al. 2011). Individual deletions of
either isoform result in replication defects (Lin et al. 2011) as does treatment of parasites
with the TgNDH2-1 inhibitor 1-Hydroxy-2-Dodecyl-4(1H)Quinolone (HDQ).

Since

treatment with MMV006169 matches the phenotype seen with HDQ, and the compounds
both fit class B inhibitors of human ND2, we tested the hypothesis that MMV006169
inhibits TgNDH2-1 and/or TgNDH2-2, but saw no positive interactions with either
isoform by yeast three-hybrid. Taken together, these experiments suggest that
MMV006169 may be working primarily through interactions with host cell NADH
dehydrogenase, although we cannot eliminate the possibility that attaching a linker to
MMV006169 prevents it from interacting from another relevant target.
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Chapter 3 – Table 1: IC50 values for MMV006169 resistant parasite clones
IC50 values extrapolated from YFP-based growth assays performed on MMV006169
resistant clones. Clones were continuously cultured in 1% DMEM containing 3 µM
(EC90) MMV006169. To conserve compound, clones were only assayed until a clean IC50
curve was obtained with clones 1, 2, 8, and 9 being screened once, clones 3, 4, 6, and 7
screened twice, and non-mutagenized screened in triplicate. Clone 5 did not recover after
freeze thaw.
Clone #
IC50 (μM)
1
3.35
2
2.13
3
4.41
4
3.39
6
4.06
7
1.80
8
3.42
9
2.30
Non-mutagenized
1.22
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Chapter 3 – Table 2: Titering 3-AT

3-AT was plated at the concentration indicated onto SC + Glu – trp – leu media. One
hour later, CID7 (5 µM, A) or DMSO (B) were spread onto each plate. The next day,
7x107 yeast cells were plated, plates were parafilmed and stored at 30°C for 7 days. The
number of colonies per plate was recorded daily.

Days Post Plating

A)

0
1
2
3
4
5
6
7

5.00
0
0
0
0
0
0
0
2

2.50
0
0
0
0
0
3
4
5

CID7
[3-AT] μM
1.25
0.63
0
0
0
0
0
0
0
0
2
4
3
9
5
24
10
37

0.31
0
0
0
0
0
13
41
64

0.00
0
0
0
6
7
12
41
lawn

2.50
0
0
0
0
0
0
0
0

DMSO
[3-AT] μM
1.25
0.63
0
0
0
0
0
0
0
0
0
0
0
9
0
24
0
47

0.31
0
0
0
0
0
11
22
38

0.00
0
0
0
0
0
lawn
lawn
lawn

Days Post Plating

B)

0
1
2
3
4
5
6
7

5.00
0
0
0
0
0
1
2
2
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Chapter 3 – Table 3: Primers for cloning T. gondii NDH2-1 and NDH2-2
All primers were synthesized by Sigma Aldrich (The Woodlands, TX) with no special
modifications. Sequences homologous to pGADT7 are underlined and were used for
cloning in yeast.
Primer
14
15
16
17
18
19
20
21
22

Name
NDH1IVCFw
NDH1IVCRev
NDH1-500Fw
NDH1-1000Fw
NDH2IVCFw
NDH2IVCRev
NDH2-500Fw
NDH2-1000Fw
NDH2-1500Fw

Sequence (5'è3'); Sequence homolgous to pGADT7 is underlined
GAGTACCCATACGACGTACCAGATTACGCTATGGCAGGGCAGTGGCTGCG
ACAAGCCGACAACCTTGATTGGAGACTTGATCACTTGCGTCGGTCGCCGT
CGGAAGTTTCTACGAAGGC
GTCGACCTTTGCCTTCAGTC
GAGTACCCATACGACGTACCAGATTACGCTATGGCGATGCTCTTCTCCAG
ACAAGCCGACAACCTTGATTGGAGACTTGATCAGTGGTTGTAATATTCG
CCGACACCTTGACCCAAAC
CAAAGAGGACATGAGCAAG
GGCCGACACGCACCGACCC
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Chapter 3 – Figure 1: Titration of ENU

Plaque assay performed plating varying numbers of 2F1 YFP2 parasites (indicated left)
exposed to varying concentrations of ENU (indicated bottom). Below is the standard
survival curve for percent parasite survival versus concentration of ENU. Optimal
concentration of ENU determined to be 6.31 mM.

103

DMSO

MMV006169

Chapter 3 – Figure 2: MMV006169 resistant clone forms cysts after compound
treatment

2F1 YFP2 parasites were continuously cultured in 1% DMEM containing 3 µM
MMV006169 for seven days prior to fixation (3 µM corresponds to the EC90 with nonmutagenized parasites). DMSO control parasites were fixed after 24 hours. The cyst wall
was stained with TRITC-conjugated Dolichos biflorus lectin and parasites with an antiToxoplasma antibody.
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Chapter 3 – Figure 3: Clone 14 interacts with Mtx-MMV006169

Targeted yeast three-hybrid assay where growth of yeast in media lacking histidine is a
reflection of reporter activation. The positive control, CDPK1, is able to grow more
robustly in the presence of CID7 than in DMSO (red versus blue bars), implying a direct
interaction between CID7 and CDPK1. Clone #14 grows more robustly in the presence of
Mtx-MMV006169 (purple, p≤0.05) than DMSO (green) suggesting the gene-product of
clone #14 is a target of MMV006169. Bars represent mean +/- standard deviation; n=3.
Data were analyzed using paired t-tests (*p≤0.05, **p≤0.01).
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Chapter 3 – Figure 4: MMV006169 analog toxicity after 8 days

Viability of host cells was determined via ATPase assay. HFFs were exposed to 10 µM
analogs for 8-days prior to host cell lysis and quantification of ATP levels by
luminescence. Luminescence is reported as relative luminescence units (RLU). All wells
were normalized to a control with no CellTiter-Glo reagent. Sodium azide was included
to represent a “kill control” in which we know the cells are no longer generating ATP.
Bars represent mean +/- standard deviation, n=4. Data were analyzed using a one-way
ANOVA (****p≤0.0001).
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Chapter 3 – Figure 5: MMV006169 does not interact with TgNDHs by yeast threehybrid

Targeted yeast three-hybrid experiments quantifying growth of yeast in media lacking
histidine as a reflection of reporter activation. The positive control, BRADIN, is able to
grow more robustly in the presence of CID7 than in DMSO (red versus blue bars),
implying a direct interaction between the CID and TgBRADIN. NDH2-1 and NDH2-2
grow to similar levels in the presence of Mtx-MMV006169 (purple) and DMSO (green),
meaning the histidine reporter gene has not been activated. Bars represent mean +/standard deviation; n=3. Data were analyzed using paired t-tests (****p≤0.0001).
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS

Small molecule target identification is a lengthy process limited first by the
identification of potent compounds of interest. Historically, large compound libraries
have been screened with a low percentage of promising hits being identified (Carey et al.
2004, Dittmar et al. 2016). It is impossible to know what the expected success rate of for
target identification projects such as this should be, as most groups only document
successes and not failures. It is even difficult to correlate successful target identification
with compound potency. While it is true that increased potency may increase the
specificity of a compound for its protein target(s), target identification has been
successful using compounds with varying degrees of potency. For example, Compound 1
was shown to specifically inhibit TgPKG with an IC50 1 nM (Donald et al. 2002), while
atorvastatin inhibits the human quinone reductase, NQO2, with an IC50 of 50 µM
(Chidley et al. 2011). This means that every target identification endeavor is unique and
will come with its own set of challenges.
Screening of the MMV Open Access Malaria box provided us with a novel
starting point for compound discovery as the 400 compounds included in this collection
were already shown to inhibit growth of the related apicomplexan, P. falciparum.
Similarities between apicomplexans include a conserved intracellular life cycle involving
invasion of host cells, modification of a parasitophorous vacuole, secretion from
specialized organelles, and egress from host cells (Cowman and Crabb 2006, Boothroyd
and Dubremetz 2008, Treeck et al. 2011). This study identified 79 inhibitors of T. gondii
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growth, many of which were not identified in previous MMV box screens against T.
gondii (Boyom et al. 2014). Boyom et al. reported 7 inhibitors of T. gondii growth with
potencies ranging between 0.19-4.54 µM. Of these 11, only two, MMV666095 and
MMV085203, were also found in our screen. The lack of overlap between MMV box
screens could be a functional consequence of the screening assays chosen. The screen
used by Boyom et al. involved incubation of parasites with compound for 24 hours
followed by treatment with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and the electron coupling reagent
phenazine methosulfate (PMS). MTS is converted to formazan, which can be read at 490
nm absorbance. This means our assay runs for 7 days longer, has 8 times as many time
points, and is read based on fluorescence instead of absorbance. Of the 79 molecules we
identified, MMV006169 was shown to be an inhibitor of replication and invasion with no
quantifiable difference seen in two-dimensional motility.
Our targeted yeast three-hybrid experiments using TgCDC48Cy and
TgCDC48Ap were unsuccessful, however, they only included the genes cloned into the
yeast vector such that the GAL4-AD was fused to the amino-terminus of each protein. It
would be interesting to examine the effect of carboxy-terminal fusions. If these proteins
generated a functional yeast three-hybrid complex, it would suggest the previous aminoterminal fusion was preventing proper CID-target protein interaction. Both isoforms of
TgCDC48 have been shown to retain localization upon carboxy-terminal tagging, but no
attempts have been made to alter the amino terminus (Agrawal et al. 2009). Additionally,
it is known that CDC48 associates with Der1, a pore involved in the ERAD pathway. It is
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possible that CDC48 needs to be associated with this pore for proper folding or activity to
occur. T. gondii has 3 isoforms (2 localized to the endoplasmic reticulum, 1 localized to
the apicoplast) of the S. cerevisiae Der1, the most similar localizing to the endoplasmic
reticulum and having 20% identity. Rather than using yeast three-hybrid, precursor
molecules synthesized during CID generation can be immobilized to a column and used
for affinity purification experiments with either recombinantly expressed CDC48
isoforms in the presence and absence of Der1, or with whole parasite lysates to determine
if the presence of Der1 reveals an active site for MMV006169 on CDC48.
Interestingly, there is a third form of TgCDC48 (TgME49_230710) annotated in
the Toxoplasma database (www.toxodb.org, release 29). This gene has never been
studied, with very limited proteomics data available to confirm the suggested sequence.
This isoform shares 17% identity with the S. cerevisiae CDC48, which is predicted to
interact with DBeQ, 17% identity with TgCDC48Cy, and 19% identity with
TgCDC48Ap. This lack of homology suggests that this third “isoform” of TgCDC48 will
not interact with DBeQ, and thus also not MMV006169. However, it would be easy to
assess this by cloning TgME49_230710 into our yeast expression vectors and performing
targeted yeast three-hybrid analyses as previously described.
Our library scale yeast three-hybrid experiments suggest that the target of
MMV006169 may be the host cell mitochondrially-encoded NADH dehydrogenase
subunit 2.

The fragment pulled from the library encodes 739 base pairs of ND2

equivalent to 5 transmembrane domains. Yeast three-hybrid systems are notoriously poor
at detecting transmembrane domain containing proteins, as they must be retained in the
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nucleus to activate the expression of reporter genes. However, the system has worked in
some cases to isolate transmembrane domain-containing proteins (Young and Ozenberger
1995, Kajkowski et al. 1997). Since the fragment of ND2 isolated in our screen is
typically encoded on the human mitochondrial genome, it does not contain a
mitochondrial localization sequence. So, while the protein has transmembrane domains, it
does not have a targeting sequence to shuttle it away from the endoplasmic reticulum
after folding. Additionally, the yeast expression vector used in our experiments contains a
nuclear localization sequence. That sequence in conjunction with the fact that the nucleus
is contiguous with the endoplasmic reticulum might explain why this transmembrane
domain containing protein was identified in our yeast three-hybrid experiments (Laba et
al. 2014). However, it is equally likely that this interaction is the artifact of improper
protein folding or the consequence of having expressed only a fragment of the protein.
We can directly test the inhibition of ND2 by MMV006169 by performing a
mitochondrial in vitro activity assay. This works by isolating mitochondria from lysed
host cells with differential centrifugation. Mitochondria are solubilized with digitonin or
maltocide and complex 1 is immunocaptured. Substrates are mixed with MMV006169
and changes in NADH are measured spectrophotometrically (Janssen et al. 2007,
Spinazzi et al. 2012). If NADH levels are reduced we will know that ND2 is a target of
MMV006169.
The same logic described above also pertains to the targeted yeast three-hybrid
experiments performed with TgNDH2-1 and TgNDH2-2. Both were cloned as aminoterminal fusions with the GAL4-AD. It would be interesting to see if the results of the
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assay were to differ had the activation domain been fused in a different position.
Additionally, it has been previously shown that TgNDH2-1 can be functionally expressed
in Yarrowia lipolytica, which expresses a single, non-essential NDH2 and as such is the
model organism for the study of alternative NADH dehydrogenases (Kerscher 2000).
This model was used to confirm that TgNDH2-1 is the target of HDQ (Lin et al. 2008). It
would be interesting to determine if MMV006169 works on TgNDH2-1 using the same
system. It would also be useful to optimize the system such that TgNDH2-2 can be used.
Initial attempts to express TgNDH2-2 in Y. lipolytica demonstrated oxidoreductase
activity equivalent to that of having no dehydrogenase present (Lin et al. 2008). We
suspect the primary reason for this is the improper identification of mature protein start
positions. The T. gondii mitochondrial localization sequence is insufficient to target these
isoforms to the Y. lipolytica mitochondria (Lin et al. 2008). To aid in this process, the
mitochondrial NUAM protein localization sequence was fused to the predicted mature
protein start site and full length start positions of each protein. For TgNDH2-1, only the
fusion to the predicted mature start position allowed oxidoreductase activity (Lin et al.
2008). By troubleshooting the mature protein start position of TgNDH2-2, we may be
able to generate an enzyme that functions more efficiently in Y. lipolytica and as such can
be used to directly test if MMV006169 can inhibit its activity.
The most direct set of experiments to test the hypothesis that MMV006169
interacts with TgNDHs would be to generate clean TgNDH2-1 and TgNDH2-2 gene
deletions and look for a change in parasite sensitivity to compound. Proof of concept
experiments have already been performed on parasites lacking these genes in the
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presence of HDQ (Lin et al. 2011). Using CRISPR technology, we would individually
delete each isoform of the NADH dehydrogenase and replace it with a selectable marker
(Shen et al. 2014, Sidik et al. 2014). Upon confirmation of the proper genotype, we
would perform replication assays (see Chapter 2 – Materials and Methods) and look for a
change in the number of parasites present per vacuole. If we see an increase in the
number of parasites per vacuole upon compound treatment in one (or both) knockout
parasite lines, we will know that we have isolated a relevant target. If we do not, then
TgNDHs do not interact with MMV006169.
Throughout the course of this project a major problem has been trying to
determine if we have identified an inhibitor of the parasite or host cell. While the above
experiments are elegant and informative, they are also work and resource intensive. To
easily distinguish between a host cell and parasite target, we could perform experiments
where human ND2 activity is measured in the presence of MMV006169 as described
above to determine if the compound has any impact on the host enzyme (Janssen et al.
2007, Spinazzi et al. 2012). Measurements of parasite ATP levels would then be
performed in the presence of MMV006169 and other known complex 1 inhibitors such as
piercidin A and capsaicin to see if similar effects are noted on parasite ATP levels (Degli
Esposti 1998, Carey et al. 2004). These experiments would quickly tell us if the genetic
approaches described above would be worth pursuing.
The yeast strain used in this work, BAPJ69-4A, was chosen for the presence of
the negatively selectable marker, URA3, and three additional reporters ADE2, HIS3, and
lacZ under the control of galactose inducible promoters (Shaffer et al. 2012). We had
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hoped that using this strain would allow us to significantly reduce the number of false
positive clones obtained during screening to streamline the target identification process.
However, while the negative selection did prevent a large number of yeast from growing
on selective plates in the absence of CID, even our positive control experiments using
TgBRADIN and TgCDPK1 resulted only in the activation of the histidine reporter in the
presence of CID. This means that even with verified small molecule-protein interactions,
three of the reporters in this strain were non-responsive. Since the arduous processes of
SAR analysis and CID synthesis have already been completed, it would be interesting to
screen different T. gondii cDNA libraries with these MMV006169-based CIDs to see
what putative targets are identified. We currently have two different libraries in hand and
several yeast strains that can be used with different reporters for testing CID-dependent
reporter activation. Moreover, we have received a number of P. falciparum, P. yoelii, and
P. vivax cDNA libraries (generous gifts of Drs. Douglas LaCount, Purdue University, and
Lawrence Bergman, Drexel University), and we have synthesized our own C. parvum
cDNA library. All of these libraries would be of interest to screen against our current
CIDs. It would also be imperative to include human cDNA libraries in future screens to
address the possibility that the compounds are binding to host cell targets.
While yeast three-hybrid approaches have been used successfully for target
identification in T. gondii (Odell et al. 2015) and other systems (Licitra and Liu 1996,
Chidley et al. 2011) the work presented here highlights some of the complications
associated with the technology. The best possible cDNA library, most potent compound,
and well-designed CID should be in place before attempting these experiments and even
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then the target(s) of the compound of interest may not be identified. Amongst other
reasons, this could be because (1) the phenotype in the initial screening assay is based on
synergistic (multiple targets) effects of the compound, (2) the target is not present in the
library, (3) the target is not properly folded or retained in the yeast nucleus, (4) or the
target requires the presence of other proteins in a complex to maintain the conformation
necessary to interact with the compound of interest. To increase the likelihood of success,
multiple strategies for target identification should be used in parallel with yeast threehybrid. Here we attempted to perform whole genome mutagenesis to identify the target of
MMV006169, but were unsuccessful likely because the molecule is specific for the host
cell or has multiple targets.
The modular approach to CID synthesis developed by our collaborators could, in
principle, facilitate the use of other target identification approaches (Tran et al. 2013).
The intermediate molecules derivatized to some length of linker can be attached to biotin
and as such immobilized to streptavidin-coated beads for affinity chromatography or
phage display approaches. Alternatively, the precursor molecule could be labeled with a
fluorophore for use in a drug western blot. The recent advances in the field using
CRISPR technology have simplified the follow-up required once a potential target has
been identified (Shen et al. 2014, Sidik et al. 2014, Sidik et al. 2016). One can now
determine if a gene is essential based on a literature search and then generate a gene
deletion, disruption, or inducible down-regulation in one step. The resulting parasite line
is then grown in the presence and absence of compound to confirm that the correct target
was identified.
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This work has contributed to the field of apicomplexan biology by identifying a
number of potent inhibitors of T. gondii growth that could be used as biological probes to
better aid in the understanding of apicomplexan biology. More specifically, it has
outlined SAR leading to the identification of a number of replication and invasion
inhibitors of T. gondii. It has also contributed by further outlining strengths and
weaknesses of a variety of approaches to small-molecule target identification.
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APPENDIX A: ANALYSIS OF THE REPLICATION INHIBITOR MMV403679

[N.B. Structural analogs synthesized for this work produced by Stephen Ojo (University
of St. Andrews). C. parvum data presented here were generated by the joint effort of Kovi
Bessoff and Rajiv Jumani (University of Vermont).]

As mentioned in Chapter 2, our screens of the MMV Open Access Malaria box
lead us to the identification of five small molecules of interest. MMV403679, is a potent,
non-toxic inhibitor of both T. gondii and C. parvum growth (Appendix A – Figure 1;
(Bessoff et al. 2014)). The compound also inhibits T. gondii replication (Appendix A –
Figure 2). To better understand how MMV403679 inhibits T. gondii and C. parvum, we
performed extensive structure-activity relationship analyses on this compound using 38
analogs either purchased (Life Chemicals, Ontario, Canada) or synthesized (Appendix A
– Table 1). We had aimed to use this SAR to develop a novel CID for use in yeast threehybrid experiments, but never reached that point with the project.
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Appendix A – Table 1: MMV403679 structural analogs
Thirty-eight structural analogs of MMV403679 containing a conserved allopurinol
chemical scaffold. Calculated IC50 values for each analog and corresponding 95%
confidence intervals are reported. Excessively wide confidence intervals are reported as
“n/a”.

Name

Structure

T. gondii IC 50 (µM) T. gondii IC 50 95% CI C. parvum IC 50 (µM) C. parvum IC 50 95% CI

F5091-0161

0.04

(0.03-0.05)

0.06

N/A

F5091-0196

0.04

(0.010-0.17)

0.12

(0.08-0.19)

F5091-0208

0.06

(0.05-0.06)

0.07

(0.06-0.09)

F5091-0573

0.06

N/A

0.18

N/A

F5091-0036

0.07

(0.06-0.08)

0.07

(0.04-0.10)
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F5091-0230

0.09

(0.04-0.19)

0.15

(0.11-0.21)

F5091-0270

0.10

(0.08-0.12)

0.12

(0.07-0.21)

F5091-0204

0.10

(0.06-0.15)

0.08

(0.07-0.09)

F5091-0186

0.10

very wide

0.04

(0.03-0.05)

F5091-0123

0.10

(0.07-0.15)

0.08

(0.06-0.10)

SA006

0.10

(0.08-0.13)

Not screened

Not screened

F5091-0869

0.11

(0.01-2.61)

0.17

N/A
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F5091-0273

0.13

(0.11-0.14)

0.12

(0.10-0.14)

SA001

0.14

(0.11-0.17)

1.4

(0.16-12.21)

SA010

0.14

(0.12-0.17)

Not screened

Not screened

F5091-0873

0.15

(0.11-0.21)

0.21

(0.10-0.45)

F5091-0723

0.18

(0.13-0.24)

0.41

(0.24-0.71)

SA004

0.21

(0.18-0.25)

1.17

(0.93-1.47)

F5091-0038

0.22

(0.17-0.30)

0.10

(0.07-0.16)
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SA013

0.25

(0.21-0.29)

Not screened

Not screened

Reordered
F5091-0273

0.26

(0.22-0.31)

Not screened

Not screened

SA003

0.31

(0.21-0.45)

0.32

(0.26-0.39)

Synthesized
403679

0.36

(0.30-0.45)

0.65

(0.60-0.71)

SA002

0.37

(0.24-0.58)

1.11

(0.94-1.31)

F5091-0871

~ 0.3806

very wide

0.14

(0.09-0.24)

F5091-0080

0.44

(0.38-0.51)

0.57

(0.39-0.83)
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F5091-0655

0.49

(0.39-0.60)

0.20

(0.16-0.25)

SA011

0.66

(0.56-0.76)

Not screened

Not screened

F5091-0772

1.24

(0.68-2.23)

0.20

(0.17-0.24)

F2135-0883

1.21

(0.86-1.22)

0.9992

(0.91-1.10)

403679-4

1.31

(1.08-1.59)

1.032

(0.81-1.32)

SA005

1.38

(1.17-1.63)

2.24

(1.94-2.58)

F5091-0249

1.61

(1.19-2.17)

0.17

(0.14-0.21)
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SA009

2.41

(1.83-3.18)

Not screened

Not screened

SA007

3.13

(2.84-3.44)

Not screened

Not screened

F5091-0127

4.57

(3.65-5.72)

0.69

(0.53-0.90)

SA016

>18.18

N/A

Not screened

Not screened

403679-1

>18.18

N/A

>10

N/A
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Appendix A – Figure 1: MMV403679 is not toxic to human foreskin fibroblasts

Viability of host cells was determined using the Promega CellTiter-Glo ATPase assay per
manufacturer’s instructions (see Chapter 2 Materials and Methods). HFFs were exposed
to 10 µM MMV403679 for 24-hours followed by lysis of host cells and quantification of
ATP levels by luminescence. Luminescence is reported as relative luminescence units
(RLU). All samples were normalized to a control of HFFs and media with no CellTiterGlo reagent. Sodium azide (N3Na) was included as a control for host cell death where
cells are no longer generating ATP. Bars represent mean +/- standard deviation, n=3.
Data were analyzed using a one-way ANOVA (***p≤0.001).
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Appendix A – Figure 2: MMV403679 inhibits T. gondii replication

Human foreskin fibroblasts were infected with 2F1 YFP2 strain T. gondii and grown in
the presence (green) or absence (blue) of 1 µM MMV403679 for 12, 24, or 36 hours. The
average number of parasites per vacuole at each time point was determined by
immunofluorescence (n=3, ***p ≤ 0.001, **** p ≤ 0.0001 as determined by two-way
ANOVA).
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APPENDIX B: ATTEMPTS TO IDENTIFY THE TARGET(S) OF QQ-437

[N.B. Structural analogs synthesized for this work were produced by Fanny Tran
(University of St. Andrews).]

QQ-437 is a highly potent compound that has previously been shown to reduce
T. gondii proliferation. Insertional mutagenesis has provided indirect evidence that the
target of QQ-437 is adaptin 3-beta (AP3B) (Fomovska et al. 2012). We attempted to
confirm this hypothesis by cloning TgAP3B into the yeast three-hybrid vector pGADT7
and have used two different QQ-437-based chemical inducers of dimerization (CIDs)
(Appendix B – Figure 1) to screen for an interaction between QQ-437 and AP3B. These
CIDs were synthesized based on data generated in a small-scale SAR screen (Appendix B
– Table 1). Unfortunately, there was not a positive interaction between either of our CIDs
and AP3B (Appendix B – Figure 2). This may be due to insufficient SAR leading to
suboptimal positioning of linker attachment or because AP3B is not the biologically
relevant target of QQ-437 in T. gondii. To test the latter hypothesis, I have screened both
CIDs against our T. gondii cDNA library and was unable to isolate any true interactions
via yeast three-hybrid.
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Appendix B – Table 1: QQ-437 structural analogs

Structures of QQ-437 and 11 structural analogs. Calculated IC50 values for each analog
and corresponding 95% confidence intervals are reported. Excessively wide confidence
intervals are reported as “n/a”.

Name

Structure

T. gondii IC50 (uM)

T. gondii IC50 95% CI

FT07.134.1

0.00009324

(0.00005-0.00015)

QQ437

0.004053

(0.002-0.006)

FT07.131.8a

0.005604

(0.004-0.007)

FT14.009.3

0.01622

(0.01-0.03)

FT07.168.3

0.07419

(0.06-0.10)
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FT07.135.8

0.1591

(0.12-0.20)

QQ437-Azide

0.2764

(0.24-0.31)

FT07.059.3

0.3971

(0.20-0.79)

FT14.028.3

2.269

(2.09-2.47)

FT07.067.3

>18.18

N/A

FT07.068

>18.18

N/A

FT07.070.3

>18.18

N/A
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A)

B)

Appendix B – Figure 1: Structures of QQ-437-based CIDs

A) Structure of QQ437CID1. B) Structure of QQ437CID2. QQ-437 structure is
highlighted in pink, linker in green, and methotrexate is shown in blue.
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Appendix B – Figure 2: Targeted yeast three-hybrid suggests QQ-437 does not
interact with AP3B.

Growth of yeast in media lacking histidine is a reflection of reporter activation. The
positive control, pGADBRADIN, is able to grow more robustly in the presence of CID7
than in DMSO (red versus blue bars), implying an interaction between CID7 and
BRADIN. pGADAP3B grows to the same level in the presence of (A, purple)
QQ437CID1, (B, purple) QQ437CID2, and DMSO (green), meaning no reporter
activation is seen. Bars represent mean +/- standard deviation; n=3. Data were analyzed
using paired t-tests (****p≤0.0001).
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APPENDIX C: SCREENING A SUBSET OF THE NIH CLINICAL
COLLECTION

[N.B. The full NIH Clinical Collection screening against C. parvum and selection of this
subset of molecules was performed by Kovi Bessoff (University of Vermont)]

As part of an effort to identify novel inhibitors of T. gondii growth, we received a
subset of compounds taken from the NIH Clinical Collection (NCC) for screening. The
NCC is comprised of 719 FDA-approved small molecules, classified as both drug and
drug-like, with known mechanisms of action. Our collaborators screened the entire
collection against the related apicomplexan C. parvum and a subset of molecules that
showed inhibitory activity were provided for screening against T. gondii (Bessoff et al.
2013). Using the previously described YFP-based growth assay (Chapter 2 Materials and
Methods) these compounds were screened in triplicate (Appendix C – Figure 1). The
majority of the compounds inhibited T. gondii growth with sub-micromolar potency, and
many of them have known targets in human cells or are likely working through inhibition
of DNA replication. We aimed to determine if these compounds inhibit T. gondii in a
manner similar to that of host cells. This would help identify conserved pathways and
thus aid in the understanding of general parasite biology. Moreover, if compounds were
found to work differently, they could be used to tease apart parasite biological
mechanisms.
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Appendix C – Table 1: Efficacy of NIH Clinical Collection compounds on T. gondii
growth.
YFP-based growth assays were performed on 17 NCC compounds as previously
described. Each compound was serially diluted to yield a total of 11 test concentrations
that were screened in triplicate.

Homoharringtonine
Docetaxel
Digoxin
Hexachlorophene
Triptolide
Minocycline
5-Fluorouracil
Oligomycin C
Floxuridine
Chloroxine
Carmofur
Indomethacin
Doxycycline
Tegaserod Maelate
6-Azauridine
Glipizide
Mevastatin

T. gondii IC50 (μM)
0.03029
0.03855
0.07251
0.09068
0.1309
0.2278
0.2343
0.396
0.4183
0.5631
0.8335
1.234
1.311
5.301
>18uM
>18uM
>18uM
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T. gondii IC50 95% CI
0.02048 to 0.04479
0.02866 to 0.05184
0.06177 to 0.08512
0.06052 to 0.1359
Very Wide
0.09084 to 0.5713
0.1968 to 0.2791
0.2277 to 0.6887
0.1770 to 0.9885
0.2798 to 1.133
0.4586 to 1.515
0.7927 to 1.920
0.6706 to 2.565
3.552 to 7.910
N/A
N/A
N/A

APPENDIX D: TARGETED YEAST THREE-HYBRID FOR INTERACTION
BETWEEN 118793 AND EG5

During the original small-molecule screen performed in our lab, 118793 was
identified as one of the more potent inhibitors of T. gondii invasion (Carey et al. 2004). In
mammalian cells it has been shown that 118793 interacts with the mitotic kinesin Eg5
(Hotha et al. 2003). Preliminary structure-activity relationship (SAR) data suggest that
the target in T. gondii is not likely a homolog of this mammalian protein. However,
mammalian Eg5 represents an excellent positive control for drug-protein interaction
studies involving 118793. To develop this positive control, we amplified full-length
mammalian Eg5 from cDNA generated from human foreskin fibroblasts (HFFs) and
cloned it into the yeast vector pGADT7. The resulting plasmid was then co-transformed
into AH109 with pGBKeDHFR and used in targeted yeast three-hybrid experiments
(Chapter 2 Materials and Methods) with the previously generated CIDs 2 (ST501611)
and 3 (ST504011) at varying concentrations. At that point in our development of the
yeast three-hybrid system, there was no positive control to use in these assays, so they
were performed only with the addition of a DMSO control. No reporter activation was
seen upon the addition of either CID (Appendix D – Figure 1). Without a positive control
we cannot conclude that 118793 cannot interact with Eg5, but these experiments obtained
negative results.
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Appendix D – Figure 1: Targeted yeast three-hybrid suggests Eg5 does not
interact with 118793.

Growth of yeast in media lacking adenine is a reflection of reporter activation.
PGADFLEg5-containing yeast grows to the same level in the presence of CID2 (1 and 10
µM, red and green), CID 3 (1 and 10 µM, purple and orange), and DMSO (green),
meaning no reporter activation occurred. Bars represent mean +/- standard deviation;
n=3. Data were analyzed using paired t-tests.
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APPENDIX E: GENERATING THE TgUNC ANTIBODY AND DEFINING
CELLULAR LOCALIZATION

[N.B. The rabbit work including antigen injections and bleeds were done by Cocalico
Biologicals (Stevens, PA). Testing of antibody against Sf9 cell samples was performed by
Anne Kelsen (University of Vermont).]

TgUNC, a UCS-domain containing protein, has been shown to aid in TgMyoA
folding, but the protein itself has never been characterized in T. gondii (Bookwalter et al.
2014). UCS-domain containing proteins historically interact with myosins and heat shock
proteins and are found in many different organisms including a number of apicomplexan
parasites. First attempts to characterize the gene involved localizing it in intact parasites.
Using both FLAG- and 3xMyc-tagged TgUNC (RH ΔhxgprtΔku80) it was determined
that the protein localizes in a punctate manner to the parasite cytosol (Appendix E –
Figure 1).
To further characterize the protein, we attempted to generate a TgUNC antibody.
The UCS domain (last 1327bp) of TgUNC was sub-cloned into pCR 2.1-Topo vector
using TA cloning. The resulting plasmid was digested with HindIII and NdeI to excise
the UCS domain. The 1.3kb fragment was then ligated into pre-digested (HindIII/NdeI)
pET28a and sequenced to ensure proper insertion and the plasmid was renamed
pETUCSDCln1. pETUCSDCln1 was transformed into BL21-CodonPlus(DE3)-RIL
competent cells for bacterial expression. A negative control of pET28a transformed into
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BL21-CodonPlus(DE3)-RIL competent cells was included in parallel in all induction
experiments. A single colony of bacteria was used to inoculate 3 mL of LB supplemented
with 50µg/mL kanamycin and incubated overnight at 37°C. The next day, the culture was
diluted 1:20 and grown with shaking at 37°C for 2 hours. Uninduced samples (1 mL
each) were removed and prepared for analysis on an SDS-PAGE gel. The remaining
culture was induced by adding 1 mM IPTG and incubated with shaking at 37°C for 2
hours. Whole cell lysate samples were removed and prepared for loading on an SDSPAGE gel. The remaining cells were pelleted, frozen, thawed, and resuspended in B-PER
Bacterial Protein Extraction Reagent mixed with lysozyme and DNAse. The large bands
shown between 37 and 50 kDa show the bacterially expressed UCS domain (Appendix E
– Figure 2, white box). These bands are notably absent from the empty vector control.
Ten pre-bleed samples were provided by Cocalico Biologicals (22-31) for
examination. Western blots were performed on T. gondii RH lysate using pre-bleed antisera as primary antibody (1:500 and 1:2000) and goat anti-rabbit (1:20000) as secondary
antibody (Appendix E – Figure 3). Anti-sera 30 and 31 were only screened at 1:500 due
to lack of space on the SDS-PAGE gel. Pre-bleed anti-sera 24, 29, 30, and 31 were
eliminated from further study due to excessive cross-reactivity between the anti-sera and
RH lysate. Anti-sera samples 22, 23, 25, 26, 27, and 28 were screened by
immunofluorescence to confirm lack of reactivity against T. gondii (Appendix E – Figure
4). From this subset, rabbits 22 and 26 (renamed UVT149 and UVT150 by Cocalico
Biologicals) were injected with UCSD (UCS domain only) antigen to generate
antibodies. Subsequent bleeds from each animal were screened by western blot for
147

reactivity against RH ΔhxgprtΔku80, 3xMYC- (UCS3xMYCCln1), or FLAG-tagged
(UCSFLAGCln4) TgUNC lysates to confirm that TgUNC could be detected (Appendix E
– Figure 5). UVT150 appears to be the stronger antibody by western blot, while UVT149
is stronger by immunofluorescence based on co-localization with 3xMYC-tagged
parasites (Appendix E – Figure 6). Additionally, UVT150 was screened against
baculovirus/Sf9 recombinantly expressed full-length TgUNC (FL TgUNC), TgUNC
lacking the TRP domain (ΔTPR), and the UCS-domain (UCS only) of TgUNC alone
(Bookwalter et al. 2014). All recombinantly expressed proteins were detected using
UVT150 (Appendix E – Figure 7).
In addition to the generation of an antibody, parasites lacking TgUNC were
generated using the DiCre system (Andenmatten et al. 2012). The conditional deletion
will circumvent the potential issue of protein compensation, where a related protein takes
the place of TgUNC. It also allows us to look at the phenotypic consequences of the gene
deletion if TgUNC is essential. The DiCre system requires the use of MG311 parasites,
which are RH ΔhxgprtΔku80 strain parasites with multiple copies of dimerizable Cre
recombinase randomly integrated into the genome. To use this strain, 3xMYC-tagged
TgUNC was cloned into pG265, between two loxP sites. The 5’ and 3’UTRs were also
cloned into the vector to ensure proper targeting to the TgUNC locus. The resulting
parasites were selected in 50 µg/mL xanthine and 25 µg/mL mycophenolic acid. To
induce gene excision, parasites were incubated in 50 nM rapamycin for 3 hours followed
by syringe release and plating on a fresh monolayer of HFFs. After 48 hours, parasite
lysate was prepared. Evidence in the field suggests that a deletion of TgUNC results in
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the loss of TgMyoA (along with all other myosins) (Graindorge et al. 2015). To confirm
the excision of TgUNC, a quantitative western blot for TgMyoA normalized to GRA8
was performed. The addition of rapamycin resulted in the depletion of TgMyoA in two
independent clones (D3 and D6), with no loss of signal seen in the non-loxP flanked
3xMYCUCSCln1 (Appendix E – Figure 8).
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Appendix E – Figure 1: Subcellular localization of TgUNC

3xMYC-tagged TgUNC localizes to the T. gondii cytosol (red, top). DeltaVision
deconvolution microscopy (bottom) shows that TgUNC has a punctate arrangement in
the cytosol. A TgGAP45 antibody was used to outline the entire tachyzoite (green).
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Appendix E – Figure 2: IPTG Induction of TgUNC UCS domain expression.

Induced and uninduced samples of BL21 bacteria containing pETUCSDCln1. Bacterially
expressed UCSD is highlighted between 50 and 37 kDa in the induced insoluble fraction
(white box, lanes 5 and 6), but is notably absent from the uninduced samples (lanes 13
and 14).
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Appendix E – Figure 3: Screening pre-bleed samples against RH lysate

T. gondii RH lysate (equivalent of ½ of a T175 flask in large vacuoles) was run on small
SDS-PAGE gel. Samples were probed using indicated pre-bleed at 1:500 and 1:2000
overnight (except 30 and 31, 1:500 only), followed by secondary probing with goat antirabbit antibody (1:20000). Robust cross-reactivity seen in pre-bleeds 24, 29, 30, and 31
resulted in their discontinuation from consideration for antibody generation.
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Appendix E – Figure 4: Immunofluorescence with pre-bleeds against T. gondii

RH strain T. gondii was probed with each pre-bleed (1:500) followed by goat anti-rabbit
antibody (1:500). Pre-bleeds showing parasite fluorescence (23, 25, 27, and 28) were
eliminated from further consideration.

153

UCSFLAGCln4

UCS3xMYCCln 1

ΔHXGPRTΔKU80

UCSFLAGCln4

UCS3xMYCCln 1

ΔHXGPRTΔKU80
Red=IMC1
Green=Bleed

250
150
100
75

50

25

UVT149

UVT150

Appendix E – Figure 5: Western blot against T. gondii lysates using UVT149 and
UVT150

RH ΔhxgprtΔku80, 3x-MYC-, and FLAG-tagged TgUNC parasite lines were probed with
UVT149 and UVT150 bleeds at 1:500 (6 boosts, 070114) followed by goat anti-rabbit
antibody (1:20000). UVT149 does not show reactivity with antibody, while UVT150
shows specificity in all three parasite lines (white box).
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Appendix E – Figure 6: Immunofluorescence of UCS3xMYCCln1 parasites using
UVT149 and UVT150

3x-MYC-tagged parasites were stained with UVT149 and UVT150 bleeds at 1:500
(terminal bleed, 102014) followed by goat anti-rabbit antibody (1:500). UVT149 (top,
green) staining co-localizes with anti-MYC staining (red), while UVT150 appears nonspecific (bottom, green).
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Appendix E – Figure 7: Western blot against recombinantly expressed TgUNC
(full-length and truncations) using UVT150

Baculovirus/Sf9 recombinantly expressed full-length TgUNC (FL TgUNC), TgUNC
lacking the TRP domain (ΔTPR), and the UCS-domain (UCS only) of TgUNC probed
with UVT150 terminal bleed. All recombinantly expressed forms of TgUNC are detected
by UVT150, with little cross-reactivity in the cells only control.
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Appendix E – Figure 8: Inducible knock-out of TgUNC results in loss of TgMyoA

Quantified western blot of non-loxP flanked 3xMYC-tagged TgUNC (C13) versus loxP
flanked 3xMYC-tagged TgUNC expressing parasites with and without rapamycin
(TgMyoA=100 kDa, TgGRA8=38 kDa, n=1).
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APPENDIX F: DRUG AFFINITY RESPONSIVE TARGET STABILITY AS AN
APPROACH TO TARGET IDENTIFICATION

[N.B. Baculovirus expressing recombinant TgMLC1 was generated by Jacqueline Leung
(University of Vermont).]

Drug affinity responsive target stability (DARTS) is a genomics-based approach
to target identification. The approach is based on the assumption that the binding of a
small molecule/drug of interest to a target protein may stabilize that protein’s structure in
such a way as to make it less susceptible to proteolysis (Lomenick et al. 2009, Lomenick
et al. 2011, Pai et al. 2015). DARTS was chosen because it allows one to analyze lower
affinity reactions that are typically lost using other techniques, it requires no chemical
modification or derivatization of the target protein or small molecules, and can be used
with any cell or tissue type. TachypleginA binds covalently to TgMLC1 and upon
binding results in an electrophoretic mobility shift associated with the formation of a
225.118 Da adduct on the protein (Heaslip et al. 2010, Leung et al. 2014). This pair
presented a unique way to visually troubleshoot DARTS, as unbound, unmodified
TgMLC1 should be degraded while the bound form should remain intact (Appendix F –
Figure 2B). The assay was performed using Sf9 cell extracts made using PBS
supplemented with small amounts of CaCl2 and a concentration of subtilisin between 510 ng per 10 µL of extract. It was found that the addition of TachypleginA to
recombinant TgMLC1 did not protect the protein from proteolysis (Appendix F – Figure
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2A). This is demonstrated by the disappearance of both the upper and lower bands in
each TachypleginA treated sample. The same results were obtained using an alternate
protease (pronase). This technique has been unsuccessful thus far in our hands and needs
further optimization.
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Appendix F – Figure 1: Schematic of DARTS mechanism

Lysate or extract is prepared and incubated with the small molecule/drug of interest (or
vehicle control). The protease of choice is then added to each sample and incubated for a
pre-optimized amount of time. Samples are prepared for running on SDS-PAGE gel
followed by western blot or staining to visualize proteolysis.
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Appendix F – Figure 2: DARTS using TgMLC1 and TachypleginA

A) DARTS using whole cell lysate. Sf9 cells expressing recombinant Myosin Light
Chain-1 were harvested and treated with 40mM TachypleginA or equivalent volume of
DMSO. Samples were subjected to subtilisin digestion, run on an SDS-PAGE gel, and
analyzed via western blot with an anti-MLC1 antibody. B) Predicted DARTS outcome
for recombinant TgMLC1 protected by TachypleginA.
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APPENDIX G: DETERMING IF TgBRADIN CAN INTERACT WITH p38α
MAP KINASE

[N.B. Appendix G – Figure 1 was generated by Gary Ward (University of Vermont).]

While our paper discussing TgBRADIN as a target of Compound 2 was under
revision, another group published an analysis of TgBRADIN (which they named GRA24)
(Braun et al. 2013, Odell et al. 2015). TgBRADIN/GRA24 was shown to be secreted by
the parasite into the host cell cytosol where it associates with p38α MAP kinase (p38α
MAPK). This presented us with the hypothesis that TgBRADIN/GRA24 interacts
indirectly with Compound 2 through p38α MAPK. To directly test this an
immunoprecipitation of the entire yeast three-hybrid complex (Appendix G – Figure 1)
was attempted, where protein G beads and an anti-HA antibody were used to pull-down
the HA-tagged c-terminal portion of TgBRADIN (Screen 3 Hit#4). If an interaction is
occurring one would be able to detect TgBRADIN, p38α MAPK, and LexA in the
presence of Mtx-Cmpd2.1. Additionally, immunoprecipitation with free Compound 2
(C2) should result in the disappearance of TgBRADIN. Standard western blots were
performed and it was determined that both p38 and LexA were detectable in whole cell
lysates, but only LexA was found in immunoprecipitations with (bound) or without
Compound 2 competition. Both p38 and LexA were absent from the eluate collected after
Compound 2 competition (Appendix G – Figure 2A). Upon striping and re-probing the
blot, it was determined that TgBRADIN was found in all samples except the eluate
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(Appendix G – Figure 2B). Taken together, these data suggest that TgBRADIN is not
interacting with Compound 2 through p38α MAPK.
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Appendix G – Figure 1: Hypothesized role of p38α MAPK in yeast three-hybrid
complex

Yeast three-hybrid schematic where p38α MAPK (yellow) acts as a bridging protein
between compound 2 (blue) containing CID (MTX-Cmpd2.1) and TgBRADIN (red). The
methotrexate moiety of MTX-Cmpd2.1 (green) interacts with the DNA-binding domain
(DBD, purple). The activation of reporter genes occurs upon interaction of the quaternary
complex.
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Appendix G – Figure 2: p38α MAPK is not present in yeast three-hybrid complex

Yeast containing the functional TgBRADIN yeast three-hybrid complex were grown to
log phase in the presence of CID. HA-tagged TgBRADIN was immunoprecipitated (IP)
using protein G beads and an anti-HA antibody. The resulting IP was run on an SDSPAGE gel including whole cell lysate, IP with and without compound 2 competition, and
the eluate isolated from the compound 2 competition. The gel was prepared for western
blot and probed for A) p38α MAPK (green) and LexA-DHFR (red) and B) HATgBRADIN (green) and LexA-DHFR (red). * Indicates cross reactivity with heavy
chain.

165

APPENDIX H: USING 3-DIMENSIONAL MOTILITY ASSAYS TO EXAMINE
THE ROLE OF CALCIUM IN T. GONDII MOVEMENT

It has been shown that calcium is involved in parasite motility, conoid extension,
microneme secretion, invasion, and egress (Carruthers et al. 1999, Carruthers and Sibley
1999, Lovett and Sibley 2003, Wetzel et al. 2004, Del Carmen et al. 2009, Borges-Pereira
et al. 2015). However, the spatial and temporal dynamics of calcium fluctuations are
unclear. For these experiments, we used a microscopic assay, first developed in our
laboratory, which tracks parasites as they move in a three-dimensional matrix (Leung et
al. 2014). We expanded on this powerful assay by using T. gondii parasites transfected
with genetically encoded calcium indicators (i.e., GCaMPs) (Borges-Pereira et al. 2015)
to track changes in calcium concentration as parasites move (Appendix H – Figure 1).
This allows us to measure changes in intracellular calcium concurrently with velocity
(Appendix H – Figure 2), displacement, twist, acceleration, and curvature with the
objective of determining if there is a correlation between calcium fluctuation and any of
these parameters. We have optimized the assay with respect to matrigel
concentrations/batches, intensity of light, imaging time, heating conditions, and image
interpretation methods. Using this optimized system, we have generated preliminary data
suggesting that there is an increase in parasite calcium levels prior to increases in parasite
speed (Appendix H – Figure 1 and Figure 2 *). Using the results of the aforementioned
experiments, we have performed experiments using small molecules known to alter
calcium oscillations in the parasites. We used caffeine, which has been shown to lengthen
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calcium oscillations, calmidazolium, which shortens the oscillations (Wetzel et al. 2004),
and thapsigargin, which can cause shallow rapid or long slow oscillations (Nagamune et
al. 2007). These experiments have been completed in triplicate and have been run
through the existing analysis software (designed to analyze velocity, curvature, torsion,
and acceleration) generated with the help of Mark Rould, but no notable phenotypes were
seen with respect to log KS values (Leung et al. 2014). Log KS values represent the
statistical Kolmogorov–Smirnov test. This test is used to show variation both within
(same treatment and parasite line) and between (different treatments and/or parasite lines)
data sets. In these experiments, we noted a lot of variability within datasets, meaning that
DMSO-treated samples of the same parasite line did not behave in the same manner
across biological replicates. As such we cannot conclude that large variation in the data
are due to compound treatment and not just day-to-day variation. Work is currently
underway to modify the existing software such that it is capable of developing a spatially
and temporally resolved model of calcium levels in moving parasites.
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Appendix H – Figure 1: Increases in calcium precede increases in velocity along
parasite trajectories

Visualization of calcium levels (intensity sum, left) and velocities (right) along two
parasite trajectories (A and B).
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Appendix H – Figure 2: Oscillations in intracellular parasite calcium levels during
motility

Graphical representation of simultaneous measurements of intracellular calcium level
(blue) and speed (red) of GCaMP6-expressing parasites as they move through Matrigel. *
Indicates a pane where a spike in calcium can be seen before an increase in speed across
the majority of the graph.
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